Companion diagnosis of human CEACAM1 targeted therapeutic agents

By selecting appropriate antibody therapies through genotyping, the problem of poor treatment efficacy for CEACAM1-related diseases in existing technologies has been solved, enabling precision treatment for individuals with different genotypes and enhancing the treatment effect for cancer and chronic infections.

CN119013042APending Publication Date: 2024-11-22THE BRIGHAM & WOMEN S HOSPITAL INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032596.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-03
Filing Date
2023-02-03
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Current technologies make it difficult to select effective antibody therapies based on CEACAM1 genotypes, resulting in poor treatment outcomes for CEACAM1-related diseases or disorders.

Method used

The CEACAM1 genotype of the subject is determined by genotyping, and appropriate antibodies or drugs with antigen-binding domains are selected for treatment, including targeted drug selection for individuals with homozygous wild-type, heterozygous, or homozygous alleles.

Benefits of technology

It improves the treatment efficacy of CEACAM1-related diseases or disorders, reduces disease symptoms, and enhances the immune response, particularly in the treatment of cancer and chronic infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013042A_ABST
    Figure CN119013042A_ABST
Patent Text Reader

Abstract

Provided herein are methods and compositions for determining whether a CEACAM1 antibody or antigen binding agent is administered as treatment to a subject diagnosed with a CEACAM1-related disease or disorder.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 306,147, filed on February 3, 2022, under 35 U.S.C. §119(e), the contents of which are incorporated herein by reference in their entirety. Government support

[0002] This invention was made with government support under Grant No. DK51362 awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention. Sequence Listing

[0003] This application contains a sequence listing, which has been submitted in XML format through the Patent Center and is incorporated herein by reference in its entirety. The XML copy was created on February 2, 2023, named "043214-191430USPX_SL.xml", and is 23,259 bytes in size. Technical Field

[0004] The technology described herein relates to the fields of molecular biology and medicine. More specifically, the technology relates to determining an appropriate therapy for treating a subject suffering from a CEACAM1-related disease or disorder. Background Art

[0005] Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a member of the carcinoembryonic antigen (CEA) family of immunoglobulin (Ig)-like transmembrane glycoproteins. CEACAM family members are involved in cell-cell recognition and regulate a range of cellular processes from shaping tissue architecture and neovascularization to regulation of insulin homeostasis and T-cell proliferation. The CEACAM family includes CEACAM1, CEACAM3, CEACAM5, CEACAM6, CEACAM7, CEACAM8, CEACAM16, CEACAM18, CEACAM19, CEACAM20, and CEACAM21.

[0006] The immune system protects the body from foreign invaders and diseased cells; but immune disorders, especially those related to T-cell tolerance (such as cancer), can wreak havoc. According to the latest data from the World Health Organization, 10 million people were diagnosed with cancer and 6 million died from cancer in the world in 2000. In addition, statistics show that the incidence of cancer is on the rise worldwide. In the United States, for example, it is predicted that 50% of people currently alive will be diagnosed with some form of cancer at some point in their lifetime.

[0007] Modern technology, such as the use of hybridomas, provides a source of highly specific and potent monoclonal antibodies that can be used in common diagnostic and clinical procedures. Summary of the invention

[0008] Diseases or disorders in which CEACAM1 plays a role in pathology can be treated with CEACAM1 inhibitors. Antibodies that bind to CEACAM1 or constructs comprising antigen binding domains, portions or fragments thereof can be used as inhibitors of the function of the protein. However, allelic variation in CEACAM1 affects the epitopes displayed by specific CEACAM1 polypeptides, making some antibodies more effective than others. The technology described herein relates to methods and compositions for determining therapy for a subject diagnosed with a CEACAM1-related disease or disorder by detecting the subject's genotype and then determining whether to administer an antibody or antigen binding agent that binds to a specific face or domain of CEACAM1.

[0009] In one aspect, described herein is a method comprising: receiving the results of a hCEACAM1 genotyping assay performed on a sample from a subject in need of therapy for a CEACAM1-related disease or disorder; and selecting therapy with an agent comprising an antibody or antigen binding domain that binds an epitope in the GF-CC' domain of CEACAM1 when the subject's hCEACAM1 genotype is homozygous wild type for A49, Q89, Q44, and Y34, or heterozygous for A49V, Q89H, Q44L, and / or Y34C; and, selecting therapy with an agent other than an agent comprising an antibody or antigen binding domain that binds an epitope in the GF-CC' domain of CEACAM1 when the subject's hCEACAM1 genotype is homozygous for the A49V, Q89H, Q44L, and / or Y34C hCEACAM1 alleles.

[0010] In another aspect is a method comprising: genotyping a sample from a subject in need of therapy for a CEACAM1-related disease or disorder to detect the subject's hCEACAM1 genotype; and, when the subject's hCEACAM1 genotype is homozygous wild type of A49, Q89, Q44 and Y34, or heterozygous for A49V, Q89H, Q44L and / or Y34C, selecting therapy with an agent comprising an antibody or antigen binding domain that binds an epitope in the GF-CC' domain of CEACAM1; and, when the subject's hCEACAM1 genotype is homozygous for the A49V, Q89H, Q44L and / or Y34C hCEACAM1 alleles, selecting therapy with an agent other than an agent comprising an antibody or antigen binding domain that binds an epitope in the GF-CC' domain of CEACAM1.

[0011] In one embodiment of this aspect and all other aspects provided herein, the subject suffers from or has been diagnosed with a chronic disease.

[0012] In one embodiment of this aspect and all other aspects provided herein, the chronic disease is selected from the group consisting of: cancer; persistent infection; and chronic viral infection.

[0013] In one embodiment of this aspect and all other aspects provided herein, the subject is a human.

[0014] In one embodiment of this aspect and all other aspects provided herein, the antibody or antigen binding domain that binds to an epitope of the GF-CC' domain of CEACAM1 comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region and the light chain variable region each comprise CDR1, CDR2 and CDR3; and the sequence of CDR1H comprises the sequence X1HX2X3S (SEQ ID NO: 1); Xi is A, D, N or S; X2 is A or G; and X3 is an amino acid with a hydrophobic side chain, including I or M; the sequence of CDR2H comprises the sequence TISSGGTYTYYPDSVKG (SEQ ID NO: 2); the sequence of CDR3H comprises the sequence HX4X5DYX6PX7WFAX8 (SEQ ID NO: 3); X4 is D, G or P; X5 is F or P; Xe is D or F; X7 is A or Y; and Xs is L, H or F; the sequence of CDR1L comprises the sequence RANSAVSYMY (SEQ ID NO: 4); NO:4); the sequence of CDR2L comprises the sequence LTSNRAT (SEQ ID NO:5); the sequence of CDR3L comprises the sequence QQX9X10X11X12PX13T (SEQ ID NO:6); X9 is W or N; X10 is S or T; X11 is A or an amino acid with a neutral hydrophilic side chain, including S, N and T; X12 is L, F or N; and X13 is P or F.

[0015] In one embodiment of this aspect and all other aspects provided herein, the sample is selected from the group consisting of a blood sample, a tissue sample, a tumor sample, and a cell sample.

[0016] In one embodiment of this aspect and all other aspects provided herein, the genotyping assay comprises direct probing, allele-specific hybridization, PCR, allele-specific amplification (ASA), single base extension, ARMS-PCR, Taqman, oligonucleotide ligation assay, single strand conformation analysis (SSCP), Genetic Bit Analysis and RFLP direct sequencing, mass spectrometry (MALDI-TOF) and DNA array.

[0017] In one embodiment of this aspect and all other aspects provided herein, the method further comprises administering a selected therapy.

[0018] In one embodiment of this aspect and all other aspects provided herein, the method further comprises, when the CEACAM1 genotype is A49V, Q89H, Q44L and / or Y34C heterozygous, assaying a sample containing CEACAM1 from the subject to determine the extent to which the subject's CEACAM1 is bound by an agent comprising an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1, and adjusting the amount and / or dosage of the agent to be administered based on the extent of binding of the agent to the subject's CEACAM1.

[0019] In one embodiment of this aspect and all other aspects provided herein, the assay comprises a method selected from flow cytometry, mass cytometry, immunohistochemistry, immunofluorescence or FRET assay, surface plasmon resonance, radioimmunoassay, and bio-layer interferometry.

[0020] In one embodiment of this aspect and all other aspects provided herein, the method further comprises the step of extracting genomic DNA from a sample obtained from the subject prior to genotyping.

[0021] Another aspect described herein is a method of treating a CEACAM1-related disease or disorder in a subject in need thereof, the method comprising: genotyping a sample from the subject to detect the subject's hCEACAM1 genotype; and, when the subject's hCEACAM1 genotype is homozygous wild type for A49, Q89, Q44, and Y34, administering a therapeutically effective amount of an agent comprising an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1; and, when the subject's hCEACAM1 genotype is heterozygous for A49V, Q89H, Q44L, and / or Y34C, determining the hCEACAM1-containing sample from the subject to detect the hCEACAM1 genotype of the subject; , to determine the extent to which a subject's CEACAM1 is bound by an agent comprising an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1, and administer a therapeutically effective amount of the agent, wherein the amount or dosage regimen of the administered agent is adjusted according to the extent of binding of the agent to the subject's CEACAM1; and, when the subject's hCEACAM1 genotype is homozygous for A49V, Q89H, Q44L and / or Y34C, administer a therapeutically effective amount of an agent other than an agent comprising an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1, thereby treating a CEACAM1-related disease or disorder.

[0022] In one embodiment of this aspect and all other aspects provided herein, the subject suffers from or has been diagnosed with a chronic disease.

[0023] In one embodiment of this aspect and all other aspects provided herein, the chronic disease is selected from the group consisting of: cancer; persistent infection; and chronic viral infection.

[0024] In one embodiment of this aspect and all other aspects provided herein, the subject is a human.

[0025] In one embodiment of this aspect and all other aspects provided herein, the antibody or antigen binding domain that binds to an epitope of the GF-CC' domain of CEACAM1 comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region and the light chain variable region each comprise CDR1, CDR2 and CDR3; and the sequence of CDR1H comprises the sequence X1HX2X3S (SEQ ID NO: 1); Xi is A, D, N or S; X2 is A or G; and X3 is an amino acid with a hydrophobic side chain, including I or M; the sequence of CDR2H comprises the sequence TISSGGTYTYYPDSVKG (SEQ ID NO: 2); the sequence of CDR3H comprises the sequence HX4X5DYX6PX7WFAX8 (SEQ ID NO: 3); X4 is D, G or P; X5 is F or P; Xe is D or F; X7 is A or Y; and Xs is L, H or F; the sequence of CDR1L comprises the sequence RANSAVSYMY (SEQ ID NO: 4); NO:4); the sequence of CDR2L comprises the sequence LTSNRAT (SEQ ID NO:5); the sequence of CDR3L comprises the sequence QQX9X10X11X12PX13T (SEQ ID NO:6); X9 is W or N; X10 is S or T; Xu is A or an amino acid with a neutral hydrophilic side chain, including S, N and T; X12 is L, F or N; and X13 is P or F.

[0026] In one embodiment of this aspect and all other aspects provided herein, the sample is selected from the group consisting of a blood sample, a tissue sample, a tumor sample, and a cell sample.

[0027] In one embodiment of this aspect and all other aspects provided herein, the genotyping assay comprises direct probe testing, allele specific hybridization, PCR, allele specific amplification (ASA), single base extension, ARMS-PCR, Taqman, oligonucleotide ligation assay, single strand conformation analysis (SSCP), genetic locus analysis and RFLP direct sequencing, mass spectrometry (MALDI-TOF) and DNA arrays.

[0028] In one embodiment of this aspect and all other aspects provided herein, assaying a sample containing CEACAM1 from a subject to determine the extent to which the subject's CEACAM1 is bound by the agent comprises a method selected from flow cytometry, mass cytometry, immunohistochemistry, immunofluorescence or FRET assay, surface plasmon resonance, radioimmunoassay, and biomembrane interferometry.

[0029] Another aspect described herein is an assay comprising: i) extracting genomic DNA from a biological sample from a subject in need of therapy for a CEACAM1-related disease or disorder; ii) genotyping the subject's DNA for sequences corresponding to CEACAM A49, Q89, Q44, and Y34 to determine whether the subject is homozygous wild type for A49, Q89, Q44, and Y34, or is homozygous or heterozygous for each of A49V, Q89H, Q44L, and Y34C.

[0030] In one embodiment of this aspect and all other aspects provided herein, the CEACAM1 -associated disease or disorder is selected from the group consisting of: cancer; persistent infection; and chronic viral infection.

[0031] In one embodiment of this aspect and all other aspects provided herein, the subject is a human.

[0032] In one embodiment of this aspect and all other aspects provided herein, the biological sample is selected from the group consisting of a blood sample, a tissue sample, a tumor sample, and a cell sample.

[0033] In one embodiment of this aspect and all other aspects provided herein, genotyping includes direct probe testing, allele specific hybridization, PCR, allele specific amplification (ASA), single base extension, ARMS-PCR, Taqman, oligonucleotide ligation assay, single strand conformation analysis (SSCP), genetic locus analysis and RFLP direct sequencing, mass spectrometry (MALDI-TOF) and DNA arrays.

[0034] In one embodiment of this aspect and all other aspects provided herein, the assay further comprises iii) assaying the subject's CEACAM1 protein to determine the extent to which the subject's CEACAM1 is bound by an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1.

[0035] In one embodiment of this aspect and all other aspects provided herein, the determining of step (iii) comprises a method selected from flow cytometry, mass cytometry, immunohistochemistry, immunofluorescence or FRET assay, surface plasmon resonance, radioimmunoassay and biomembrane interferometry.

[0036] Another aspect described herein is an assay comprising: i) extracting protein comprising CEACAM1 from a biological sample from a subject in need of treatment for a CEACAM1-associated disease or disorder; and ii) assaying the extracted protein for the subject's CEACAM1 to determine the extent to which the subject's CEACAM1 is bound by an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1.

[0037] In one embodiment of this aspect and all other aspects provided herein, the determining of step (ii) comprises a method selected from flow cytometry, mass cytometry, immunohistochemistry, immunofluorescence or FRET assay, surface plasmon resonance, radioimmunoassay and biomembrane interferometry.

[0038] In one embodiment of this aspect and all other aspects provided herein, the assay further comprises: iii) genotyping the subject's DNA for sequences corresponding to CEACAM A49, Q89, Q44 and Y34 to determine whether the subject is homozygous wild type for A49, Q89, Q44 and Y34, or is homozygous or heterozygous for each of A49V, Q89H, Q44L and Y34C.

[0039] In one embodiment of this aspect and all other aspects provided herein, genotyping includes direct probe testing, allele specific hybridization, PCR, allele specific amplification (ASA), single base extension, ARMS-PCR, Taqman, oligonucleotide ligation assay, single strand conformation analysis (SSCP), genetic locus analysis and RFLP direct sequencing, mass spectrometry (MALDI-TOF) and DNA arrays.

[0040] Another aspect described herein is a method of selecting an hCEACAM1 antibody therapy for a subject in need thereof, the method comprising: analyzing genomic DNA from a biological sample taken from the subject regarding the subject's genotype for hCEACAM1 alleles at loci corresponding to A49, Q89, Q44, and Y34; and, when the genotype is found to be homozygous for A49, Q89, Q44, and Y34 of CEACAM1, or for one of the A49V, Q89H, Q44L, and Y34C alleles, When a heterozygote for one or more of the A49V, Q89H, Q44L and Y34C alleles of CEACAM1 is found, a therapy with an agent other than an agent comprising an hCEACAM1 antibody or an antigen-binding fragment thereof that binds to an epitope in the GF-CC' domain of CEACAM1 is selected; or, when a homozygote for one or more of the A49V, Q89H, Q44L and Y34C alleles of CEACAM1 is found, a therapy with an agent other than an agent comprising an hCEACAM1 antibody or an antigen-binding fragment thereof that binds to an epitope in the GF-CC' domain of CEACAM1 is selected.

[0041] In one embodiment of this aspect and all other aspects provided herein, the subject suffers from or has been diagnosed with a chronic disease.

[0042] In one embodiment of this aspect and all other aspects provided herein, the chronic disease is selected from the group consisting of: cancer; persistent infection; and chronic viral infection.

[0043] In one embodiment of this aspect and all other aspects provided herein, the subject is a human.

[0044] In one embodiment of this aspect and all other aspects provided herein, the antibody or antigen binding domain that binds to an epitope of the GF-CC' domain of CEACAM1 comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region and the light chain variable region each comprise CDR1, CDR2 and CDR3; and the sequence of CDR1H comprises the sequence X 1 HX 2 X 3 S (SEQ ID NO: 1); X 1 is A, D, N or S; X 2 is A or G; and X 3 is an amino acid with a hydrophobic side chain, including I or M; the sequence of CDR2H comprises the sequence TISSGGTYTYYPDSVKG (SEQ ID NO: 2); the sequence of CDR3H comprises the sequence HX 4 X 5 DYX 6 PX 7 WFAX 8(SEQ ID NO:3); X 4 is D, G or P; X 5 Is F or P; X 6 Is D or F; X 7 is A or Y; and X 8 is L, H or F; the sequence of CDR1L comprises the sequence RANSAVSYMY (SEQ ID NO: 4); the sequence of CDR2L comprises the sequence LTSNRAT (SEQ ID NO: 5); and the sequence of CDR3L comprises the sequence QQX 9 X 10 X 11 X 12 PX 13 T (SEQ ID NO: 6); wherein X 9 W or N; X 10 is S or T; X 11 is A or an amino acid with a neutral hydrophilic side chain, including S, N, and T; X 12 is L, F or N; and X 13 It is P or F.

[0045] In one embodiment of this aspect and all other aspects provided herein, the sample is selected from the group consisting of a blood sample, a tissue sample, a tumor sample, and a cell sample.

[0046] In one embodiment of this aspect and all other aspects provided herein, the genotyping analysis includes direct probe testing, allele-specific hybridization, PCR, allele-specific amplification (ASA), single base extension, ARMS-PCR, Taqman, oligonucleotide ligation assay, single strand conformation analysis (SSCP), genetic position analysis and RFLP direct sequencing, mass spectrometry (MALDI-TOF) and DNA arrays.

[0047] In one embodiment of this aspect and all other aspects provided herein, the method further comprises administering a selected therapy.

[0048] In one embodiment of this aspect and all other aspects provided herein, the method further comprises, when the CEACAM1 genotype is heterozygous for A49V, Q89H, Q44L and / or Y34C, assaying a sample containing CEACAM1 from a subject to determine the extent to which the subject's CEACAM1 is bound by an agent comprising an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1; and adjusting the amount and / or dosage of the agent to be administered based on the extent of binding of the agent to the subject's CEACAM1.

[0049] In one embodiment of this aspect and all other aspects provided herein, the assaying comprises a method selected from flow cytometry, mass cytometry, immunohistochemistry, immunofluorescence or FRET assays, surface plasmon resonance, radioimmunoassays, and biomembrane interferometry. definition

[0050] For convenience, certain terms used herein in the specification, examples, and appended claims are collected here. Unless otherwise specified or implied from the context, the following terms and phrases include the meanings provided below. Unless otherwise explicitly stated or obvious from the context, the following terms and phrases do not exclude the meanings obtained by the terms and phrases in the art. Definitions are provided to help describe specific embodiments and are not intended to limit the claimed invention, as the scope of the invention is limited only by the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by ordinary technicians in the field to which the invention belongs.

[0051] As used herein, "reducing pathology" refers to a decrease in one or more symptoms or markers of a CEACAM1-related disease or disorder by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or more.

[0052] As used herein, "CEACAM1-associated disease or disorder" refers to a disease or disorder in which CEACAM1-mediated signaling contributes to disease pathology, e.g., CEACAM1 is expressed within pathological lesions (e.g., within cancer and tumor cells themselves) and in which the pathology can be effectively treated by inhibiting CEACAM1 function (including inhibiting the interaction of CEACAM1 with one or more CEACAM1 ligands). Symptoms of a CEACAM1-associated disease or disorder include altered patterns of immune cell infiltration in the microenvironment, anergic T cells, low levels of T cells, or an increase or elevated levels of regulatory T cells relative to an appropriate reference or control.

[0053] The terms "reduced", "reduced", "reduced" or "inhibit" used herein all refer to a statistically significant amount of a reduction or decrease in a performance, level or other parameter (e.g., the amount or relative level of a disease symptom). In some embodiments, "reduced", "reduced" or "reduced" or "inhibit" generally refers to a reduction of at least 10% in a performance, level or other parameter compared to a reference, and for example, may include a reduction of at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99% or more. "Reduced" or "inhibit" used herein does not include complete inhibition or reduction compared to a reference level. In contrast, the term "complete inhibition" is used to refer to 100% inhibition compared to an appropriate reference level. Reduction of symptoms of a given cancer may preferably be to a level within the normal range for an individual considered not to have cancer.

[0054] The terms "increased", "increase" or "enhance" or "activate" are all used herein to generally refer to an increase in a property, level or other parameter (e.g., the amount or relative level of a disease parameter, marker or symptom) by a statistically significant amount; for the avoidance of any doubt, the terms "increased", "increase" or "enhance" or "activate" refer to an increase in the level of a parameter, marker or symptom by at least 10% compared to a reference level (e.g., the level of one or more healthy individuals), such as an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a 100% increase or any increase between 10-100%, or at least about 2-fold, or at least about 3-fold, or at least about 4-fold, or at least about 5-fold, or at least about 10-fold, at least about 20-fold, at least about 50-fold, at least about 100-fold, at least about 1000-fold, or more compared to a reference level.

[0055] As used herein, an "antibody agent" is a therapeutic composition comprising an anti-CEACAM1 antibody or an antigen-binding portion or fragment thereof. The antibody or antigen-binding portion or fragment thereof in the antibody agent can be configured in a variety of forms, including but not limited to natural antibodies, humanized antibodies or chimeric antibodies, scFv, bispecific or multispecific antibodies, dAb, Fab, Fab', F(ab')2, Fd, Fd', diabodies or linear antibodies, etc.

[0056] As used herein, "CP08-based antibody agents" include antibody agents in which the antigen binding domain has a heavy chain variable region and a light chain variable region, each of which comprises CDR1, CDR2, and CDR3; and the sequence of CDR1H comprises sequence X 1 HX 2 X 3 S (SEQ ID NO: 1); X 1 is A, D, N or S; X 2 is A or G; and X 3 is an amino acid with a hydrophobic side chain, including I or M; the sequence of CDR2H comprises the sequence TISSGGTYTYYPDSVKG (SEQ ID NO: 2); the sequence of CDR3H comprises the sequence HX 4 X 5 DYX 6 PX 7 WFAX 8 (SEQ ID NO:3); X 4 is D, G or P; X 5 is F or P; X 6 Is D or F; X 7 is A or Y; and X 8 is L, H or F; the sequence of CDR1L comprises the sequence RANSAVSYMY (SEQ ID NO: 4); the sequence of CDR2L comprises the sequence LTSNRAT (SEQ ID NO: 5); and the sequence of CDR3L comprises the sequence QQX 9 X 10 X 11 X 12 PX 13 T (SEQ ID NO: 6); wherein X 9 W or N; X 10 is S or T; X 11 is A or an amino acid with a neutral hydrophilic side chain, including S, N, and T; X 12 is L, F or N; and X 13 is P or F. In one embodiment, the CP08-based antibody agent has the CDRs of SEQ ID NOs 1, 2, 3, 4, 5, 6 or affinity matured versions thereof.

[0057] As used herein, the terms "comprises / comprising / containing" with respect to compositions, methods, and components thereof refer to compositions, methods, and components thereof that are essential to the invention, but remain open to the inclusion of unspecified elements, whether essential or not.

[0058] As used herein, the term "consisting essentially of" refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristics of that embodiment of the invention.

[0059] The term "consisting of" refers to the compositions, methods, and respective components described herein, excluding any elements not recited in the description of that embodiment.

[0060] As used in this specification and the appended claims, the singular forms "a / an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "the method" includes one or more methods and / or step types described herein and / or methods and / or step types that will become apparent to a person skilled in the art after reading the present disclosure, etc. It should be understood that the above detailed description and the following examples are merely illustrative and are not intended to limit the scope of the invention. It will be apparent to a person skilled in the art that various changes and modifications may be made to the disclosed embodiments without departing from the spirit and scope of the invention. In addition, for the purpose of description and disclosure, all patents, patent applications, and publications indicated are expressly incorporated herein by reference, for example, the methodologies described in such publications that may be used with the present invention. These publications are provided only because they are disclosed prior to the filing date of the present application. In this regard, it should not be considered as an admission that the inventors do not have the right to annexe such disclosures by virtue of prior inventions or for any other reason. All statements as to the dates of these documents or representations as to the contents of these documents are based on the information available to the applicant and do not constitute any admission as to the correctness of the dates of these documents or the contents of these documents. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 The crystal structure illustrating the CEACAM1:CEACAM1 homodimer interface is shown (PDB ID: 4QXW). One CEACAM1 monomer is shown on the left and the other monomer is shown on the right. Residues Y34, Q44, Q89 and N97 form the YQQN pocket. DETAILED DESCRIPTION

[0062] Allelic variation in CEACAM1 polypeptide renders some CEACAM1-related diseases less sensitive to treatment with certain CEACAM1 inhibitors. The technology described herein relates to methods for determining whether a given subject diagnosed with a CEACAM1-related disease or disorder is a candidate for a given anti-CEACAM1 inhibitor therapy. In particular, allelic variation that affects the surface of CEACAM1 known as the GF-CC' face (also known as the FG-CC' face) affects whether an antibody that interacts with this face will be therapeutically effective. The methods described herein generally relate to methods in which a subject's genotype with respect to CEACAM1 is determined, and the genotype informs whether an antibody or antigen binding agent that interacts with the GF-CC' face is likely to be effective in treating a CEACAM1-related disease or disorder in the subject. The decision whether to administer a given antibody or antigen binding agent that interacts with the GF-CC' face of CEACAM1 or whether to administer a relatively higher or lower dose of such an agent can be informed by the genotype, which can be homozygous wild type, heterozygous for one or more allelic variants, or homozygous for one or more allelic variants that affect the GF-CC' face of CEACAM1. If the subject is homozygous for one or more allelic variants that affect the GF-CC' face, then an antibody or antigen-binding fragment that binds to the wild-type GF-CC' face will be less likely to be effective. On the other hand, if the subject is homozygous wild-type or heterozygous for one or more alleles that affect the GF-CC' face, then an antibody or antigen-binding fragment that binds to the wild-type face will be more likely to be effective, for example, at a first dose or frequency for a homozygous wild-type individual, or at a second, higher dose for a heterozygous individual.

[0063] The following describes considerations and methodology that facilitate one of ordinary skill in the art to put the technology disclosed herein into practice. CEACAM1

[0064] Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a human transmembrane glycoprotein and a member of the carcinoembryonic antigen (CEA) gene family, which is a member of the immunoglobulin superfamily. It is also known as cluster of differentiation 66a (CD66a). CEACAM1 family members are involved in cell-cell recognition and regulate a range of cellular processes from shaping tissue architecture and neovascularization to the regulation of insulin homeostasis and T-cell proliferation.

[0065] A variety of cellular activities have been attributed to the CEACAM1 protein, including roles in differentiation and arrangement of tissue three-dimensional architecture, angiogenesis, apoptosis, tumor suppression, metastasis, and regulation of innate and adaptive immune responses. Cell types that express CEACAM1 include certain tumor cells, T cells, natural killer (NK) cells, and certain macrophages.

[0066] For example, high CEACAM1 expression occurs in a variety of cancers, such as melanoma, colorectal cancer, gastric cancer, pancreatic cancer, bladder cancer, and thyroid cancer, and is associated with worse tumor progression, metastasis, and poor clinical prognosis. For example, non-small cell lung cancer (NSCLC) with high CEACAM1 expression exhibits high microvessel density, distant metastasis, and shorter median overall survival and progression-free survival. CEACAM1 expression is also closely associated with distant metastasis of pancreatic adenocarcinoma. CEACAM1 expression on tumors promotes CEACAM1-mediated inhibition of T cells and NK cells. Therefore, inhibiting the activity of CEACAM1 can inhibit tumor cell metastasis and the formation of cancer stem cell niches.

[0067] CEACAM1 is also expressed in certain immune system cells and plays a role in immunosuppression and immune cell exhaustion. For example, high CEACAM1 expression on tumor infiltrating lymphocytes (TILs) and other tumor infiltrating immune cells from gastric cancer, lung cancer, melanoma, colorectal cancer, and glioma is associated with poor prognosis. On T cells, resting (naive) T cells mostly do not express CEACAM1, while activated T cells express this protein at high levels. CEACAM1-L is the major isoform expressed on most T cells and acts as an inhibitory receptor to downregulate T cell activation and inhibit T cell function. Therefore, inhibiting CEACAM1 on T cells can restore T cell activity and increase anti-tumor responses.

[0068] CEACAM1 also mediates cell-cell adhesion through the extracellular portion of CEACAM1, which contains an IgV-like N-domain that participates in both homoaffinity (CEACAM1:CEACAM1) and heteroaffinity interactions (e.g., with CEA, CEACAM5, CEACAM8, T-cell immunoglobulin and mucin domain-containing 3 (TIM-3) protein, Helicobacter pylori adhesin HopQ, Neisseria gonorrhoeae / meningitidis opacity protein (OPA), Moraxella sp. OPa-like protein O1pA, Haemophilus influenzae outer membrane protein (OMP) P1, Haemophilus aegyptius OMP P 1, Candida albicans, and influenza viruses such as H5N1). TIM-3 was identified as a Th1-specific cell surface protein expressed on activated T cells, macrophages / NK cells, and dendritic cell subsets. TIM-3 is an activation-induced inhibitory molecule that is associated with tolerance and has been shown to induce T cell exhaustion in chronic viral infections and cancer. CEACAM1 is also expressed on activated T cells and has been shown to interact with TIM-3, an interaction that is important for TIM-3-mediated T cell inhibition.

[0069] As described above, CEACAM1 also acts as a cellular receptor on the apical membrane of mucosal cells for a variety of Gram-negative bacterial pathogens and fungal pathogens associated with human mucosa, such as Candida albicans. For example, Neisseria gonorrhoeae, Neisseria meningitidis, Moraxella catarrhalis, Haemophilus influenzae, Haemophilus aegypti, and pathogenic Escherichia coli strains all have well-characterized CEACAM1-binding adhesins. Engagement of CEACAM1 with bacterial adhesins triggers endocytosis of bacteria into epithelial cells and transcytosis of microorganisms across intact epithelial layers, allowing microorganisms to utilize CEACAM1 during mucosal colonization. In addition, CEACAM1 is associated with infection with influenza virus H5N1 and with filarial nematodes such as Wucheria bancrofti.

[0070] Human CEACAM1 (hCEACAM1) is a single-pass type I transmembrane protein expressed as 12 alternatively spliced ​​isoforms that all contain an N-terminal V-group fold of an immunoglobulin superfamily (IgV) extracellular domain, followed by up to three type 2 constant immunoglobulin (IgC2) extracellular domains (A1, B, A2), a transmembrane sequence, and a signaling cytoplasmic domain. Depending on the splicing variant, the cytoplasmic domain includes either a long (L) sequence containing two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) or a short (S) domain without ITIMs, transmitting intracellular inhibitory or non-inhibitory signals, respectively.

[0071] CEACAM1 function is triggered by intercellular or trans-binding of the IgV domain, leading to higher-order surface CEACAM1 oligomerization and subsequent intracellular signaling. Unlike other immune receptors such as T-cell inhibitory and mucin domain-containing protein 3 (TIM-3), programmed cell death protein 1 (PD-1), and programmed death ligand 1 (PD-L1), CEACAM1 acts as its own primary ligand and is also an important microbial receptor due to the high-affinity homophilic interactions of its unique IgV domain. In the basal steady state, CEACAM1 exists alternately as a monomer and a cis-homodimer on the cell surface.

[0072] The IgV domain of hCEACAM1 contains 108 amino acids arranged in nine β-strands (ABCC′C″DEFG) and folds into a conserved IgV antiparallel β-sandwich tertiary structure that is also adopted by other IgV-containing immune receptors (including TIM-3, PD-1, and PD-L1). The opposing ABED and GFCC' faces of the CEACAM1 β-sandwich are tethered by an internal salt bridge (R64:D82) that mimics the stable covalent disulfide bonds found in most Ig domains. The more predominant oligomeric form is a homodimer mediated by the high-affinity GFCC', which is conserved in other IgV domain-containing proteins. hCEACAM1 The IgVGFCC' face is unique in that the CC' loop protrudes, which is distinct from the ordered β-hairpin observed in other described IgV structures. The displaced CC' loop forms a cleft with the FG loop, exposing key residues F29, S32, Y34, V39, G41, Q44, Q89, I91, N97, and E99, which are essential for mediating homoaffinity CEACAM1 interactions. The structure of hCEACAM1, including the structure of the GF-CC' face, is presented in Huang et al., Nature 517:386-390 (2015), which is incorporated herein by reference in its entirety.

[0073] The hCEACAM1 IgV GFCC' face is the major face involved in the formation of homo- and hetero-dimers. When hCEACAM1 is converted from a dimer to a monomer by disrupting the CC' loop interactions, there are higher thermal motions and dynamic conformations within the CC' and FG loops, which accommodate monomeric hCEACAM1 species that are prone to participate in homo- and hetero-affinity interactions. Homoaffinity interactions mediated by the GFCC' face of hCEACAM1 monomers with adjacent hCEACAM1 monomers in cis or trans can restore unstable hCEACAM1 monomers to a more thermally stable dimeric form. Homodimers stabilized by the GFCC' face participate in the formation of higher-order oligomers through minor interactions mediated by the ABED face. Selective targeting of the GFCC' face of hCEACAM1 with therapeutic agents that exceed the native homo- and hetero-dimer affinities can disrupt the formation of hCEACAM1 homodimers and complexes with other ligands such as hTIM3, PD-1, and PD-L1, respectively. Additional information about the GFCC' face of CEACAM1 can be found in Huang, Yu-Hwa et al., 2015. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 517(7534):386-390; Gandhi et al., 2021. Structural basis of the dynamic human CEACAM1 monomer-dimer equilibrium. Communications Biology 4, Article number:360; and Gandhi, AK et al., 2022. Structural analysis of human CEACAM1 oligomerization. Communications Biology 5, Article number 1042; which are incorporated herein by reference in their entirety. CEACAM1-related diseases or disorders

[0074] As used herein, a CEACAM1-associated disease or disorder is one in which CEACAM1-mediated signaling promotes disease pathology and can be effectively treated to reduce such pathology by inhibiting CEACAM1 function (including inhibiting the interaction of CEACAM1 with one or more CEACAM1 ligands). Symptoms or markers of a CEACAM1-associated disease or disorder include altered infiltration patterns of immune cells in the microenvironment, anergic T cells, low levels of T cells, increased regulatory T cells, and / or increased CEACAM1 expression.

[0075] Examples of CEACAM1-associated diseases or disorders include, but are not limited to, cancer or chronic infection. In some embodiments, the subject suffers from cancer. Cancers that metastasize from their original location and seed vital organs may ultimately lead to death of the subject due to deterioration of the function of the affected organs. Hematopoietic cancers (such as leukemia) can overcome the normal hematopoietic compartments in the subject, resulting in hematopoietic failure (manifested as anemia, thrombocytopenia, and neutropenia), ultimately leading to death.

[0076] Metastasis is the spread of cancer cells from the primary tumor to other parts of the body to form areas of cancer cells that are distinct from the original tumor location. Subjects can be monitored for the presence of metastases when the primary tumor mass is diagnosed. In addition to monitoring for specific symptoms, metastases are most often detected through the use of magnetic resonance imaging (MRI) scans, computed tomography (CT) scans, blood and platelet counts, liver function studies, chest X-rays, and bone scans, alone or in combination.

[0077] Cancers include, but are not limited to, basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and CNS cancer; breast cancer; cervical cancer; choriocarcinoma; colorectal cancer; connective tissue cancer; digestive system cancer; endometrial cancer; esophageal cancer; eye cancer; head and neck cancer; stomach cancer; intraepithelial neoplasms; kidney cancer; laryngeal cancer; leukemia; liver cancer; lung cancer (e.g., small cell and non-small cell); lymphomas, including Hodgkin's lymphoma and non-Hodgkin's lymphoma; melanoma; myeloma; neuroblastoma; oral cancer (e.g., lip, tongue, mouth and throat); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancers of the respiratory system; sarcomas; skin cancer; stomach cancer; testicular cancer; thyroid cancer; uterine cancer; cancers of the urinary system, as well as various other cancers and sarcomas.

[0078] Response to anticancer therapy relates to any response of a subject's cancer or tumor to therapy, preferably to changes in tumor mass and / or volume after therapy has been initiated. Tumor response can be assessed, for example, where tumor size after intervention can be compared to initial size and dimensions (measured by CT, PET, mammography, ultrasound, or palpation), and the cellularity of the tumor can be assessed histologically and compared to the cellularity of a tumor biopsy taken before treatment was initiated. Response can also be assessed by caliper measurements or pathological examination of the tumor after biopsy or surgical resection. Responses can be recorded as follows: quantitatively, such as the percentage change in tumor volume or cellularity, or using a semi-quantitative scoring system such as residual tumor burden (Symmans et al., J. Clin. Oncol. (2007) 25: 4414-5 4422) or Miller-Payne score (Ogston et al., Breast (Edinburgh, Scotland) (2003) 12: 320-327) qualitatively such as "pathological complete response" (pCR), "clinical complete response" (cCR), "clinical partial response" (cPR), "clinical stable disease" (cSD), "clinical progressive disease" (cPD) or other qualitative criteria. Tumor response assessment can be performed early after the start of therapy, for example, after a few hours, days, weeks or preferably months. Typical response assessment endpoints are at the end of therapy or surgical removal of residual tumor cells and / or tumor bed.

[0079] Other criteria for evaluating response to anticancer therapy are related to survival, including all of the following: survival until death, also known as overall survival (wherein the death can be unrelated to the cause or related to the tumor); "recurrence-free survival" (wherein the term recurrence should include local and distant recurrences); metastasis-free survival; disease-free survival (wherein the term disease should include cancer and its related diseases). The length of such survival can be calculated by reference to a defined starting point (e.g., time of diagnosis or start of treatment) and an ending point (e.g., death, recurrence, or metastasis). In addition, the criteria for treatment efficacy can also be expanded to include response to chemotherapy, probability of survival, probability of metastasis within a given time period, and probability of tumor recurrence.

[0080] In certain embodiments, a CEACAM1 binding antibody is administered in combination with one or more additional anti-cancer / anti-tumor agents or drugs. In this case, an "anti-tumor drug" or equivalently a "cancer drug" refers to an agent administered to a subject for the purpose of treating cancer. Treating cancer may include preventing the development or progression of cancer, reducing cancer symptoms, and / or inhibiting the growth of established cancers. Various types of drugs for treating cancer are described herein and / or are known in the art. For the purposes of this specification, cancer drugs can be divided into chemotherapeutic agents, immunotherapeutic agents, cancer vaccines, hormone therapies, and biological response modifiers.

[0081] Cancer drugs work in many ways. Some cancer drugs work by targeting the physiological mechanisms unique to tumor cells. Examples include targeting specific genes and their gene products (mainly proteins) that are mutated or over- or inappropriately expressed in cancer. Such genes include but are not limited to oncogenes (oncogene) (such as Ras, Her2, bcl-2), tumor suppressor genes (such as EGF, p53, Rb) and cell cycle targets (such as CDK4, p21, telomerase). Cancer drugs can alternatively target the signal transduction pathways and molecular mechanisms that change in cancer cells. For example, targeting cancer cells by epitopes expressed on their cell surfaces is achieved by using monoclonal antibodies.

[0082] Other cancer drugs target cells other than cancer cells. For example, some drugs stimulate the immune system to attack tumor cells (such as cancer vaccines and immune checkpoint inhibitors). Although this section is about therapies that can be combined with anti-CEACAM1 antibodies, it is important to note that anti-CEACAM1 therapy promotes anti-cancer immune responses by interfering with the immunosuppressive function of CEACM1 and is therefore a class of immunotherapy. Still other drugs (such as angiogenesis inhibitors) work by attacking the blood supply of solid tumors. Angiogenesis inhibitors include basic FGF (b-FGF), VEGF, angiopoietin, angiostatin, endostatin, TNF-α, TNP-470, thrombospondin 1, platelet factor 4, CAI, and certain members of the integrin family of proteins. Because most malignant cancers can metastasize (i.e., leave the primary tumor site and seed distant tissues to form secondary tumors), drugs that hinder this metastasis are also useful in cancer treatment. Metalloproteinase inhibitors are one such drug, which inhibit enzymes that cancer cells use to persist at the primary tumor site and extravasate into other tissues.

[0083] As used herein, chemotherapeutic agents include all other forms of cancer drugs that do not belong to the category of immunotherapeutic agents or cancer vaccines. As used herein, chemotherapeutic agents include chemical agents and biological agents. These agents work by inhibiting the cell activity that the cancer cells or tumors rely on for continued survival. The categories of chemotherapeutic agents include alkylating agents / alkaloid agents, antimetabolites, hormones or hormone analogs, and a variety of anti-tumor drugs. Most, if not all, of these agents are directly toxic to cancer cells and do not require immune stimulation.

[0084] Chemotherapeutic agents currently in development or used in clinical settings include, but are not limited to, 5-FU booster, 9-AC, AG2037, AG3340, aggrecanase inhibitors, aminoglutethimide, amsacrine (m-AMSA), angiogenesis inhibitors, anti-VEGF, asparaginase, azacitidine, batimastat (BB94), BAY 12-9566, BCH-4556, bis-naphtalimide, busulfan, capecitabine, carboplatin, carmustine + Polifepr Osan, cdk4 / cdk2 inhibitors, chlorambucil, CI-994, cisplatin, cladribine, CS-682, cytarabine hydrochloride, D2163, actinomycin D, daunorubicin hydrochloride, DepoCyt, Dexifosamide, docetaxel, Dolastain, doxifluridine, doxorubicin, DX8951f, E 7070, EGFR, epirubicin, erythropoietin, estramustine sodium phosphate, etoposide (VP16-213), farnesyl transferase inhibitors, FK 317, flavopiridol, floxuridine, fludarabine, 5-fluorouracil (5-FU), flutamide, Fragyline, gemcitabine, hexamethylmelamine (HMM), hydroxycarbamide, ifosfamide, interferon α-2a, interferon α-2b, interleukin 2, irinotecan, ISI 641, krestin, lemonal DP 2202, leuprolide acetate (LHRH releasing factor analog), levamisole, LiGLA (lithium gamma-linolenate), Lodine Seeds, Lometexol, Lomustine (CCNU), Marimistat, Dichloromethyldiethylamine hydrochloride (nitrogen mustard), Megestrol acetate, Meglumine GLA, Mercaptopurine, Mesna, Mitoguanidine (methyl-GAG; methylglyoxal diguanylhydrazone; MGBG), Mitotane (op′-DDD), Mitoxantrone, Mitoxantrone hydrochloride, MMI 270, MMP, MTA / LY 231514, Octreotide, ODN 698, OK-432, Oral platinum drugs, Oral paclitaxel, Taxol PARP inhibitors, PD 183805, pentostatin (2'deoxyco-metamorphine), PKC 412, plicamycin, procarbazine hydrochloride, PSC 833, raltitrexed (Ralitrexed), RAS farnesyl transferase inhibitors, RAS proto-oncogene inhibitors, semustine (methyl-CCNU), streptozotocin, suramin, tamoxifen citrate, taxane analogs, temozolomide, teniposide (VM-26), thioguanine, thiotepa, topotecan, tyrosine kinase, UFT (tegafur / uracil), valrubicin, VEGF / b-FGF inhibitors, vinblastine sulfate, vindesine sulfate, VX-710, VX-853, YM 11, ZD 0101, ZD 0473 / Anormed, ZD1839 and ZD 9331, etc.

[0085] In certain preferred embodiments, the subject suffers from infection or has a higher risk of infection. Infection is a disease or condition caused by the presence of foreign organisms or factors that can reproduce in the host. Infection generally involves infectious organisms or factors that destroy normal mucosal or other tissue barriers. A subject suffering from infection refers to a subject in which there are objectively measurable infectious organisms or factors in the subject. A subject with a higher risk of infection refers to a subject that is prone to infection. Such subjects may include, for example, subjects known or suspected of having been exposed to infectious organisms or factors. Subjects with a higher risk of infection may also include subjects suffering from conditions associated with impaired ability to produce an immune response to infectious organisms or factors, such as subjects with congenital or acquired immunodeficiency, subjects receiving radiotherapy or chemotherapy, burn subjects, subjects suffering from traumatic injuries, subjects undergoing surgery or other invasive medical or dental surgery.

[0086] Infection can be roughly divided into bacterial, viral, fungal or parasitic infections, depending on the type of infectious organism or agent involved. Other uncommon infection types are also known in the art, including, for example, infections involving rickettsia, mycoplasma and agents that cause scrapie, bovine spongiform encephalitis (BSE) and prion diseases (such as kuru and Creutzfeldt-Jakob disease). Examples of bacteria, viruses, fungi and parasites that cause infection are well known in the art. Infection can be acute, subacute, chronic or latent, and can also be local or systemic. In addition, in the host, during at least one stage of the life cycle of an infectious organism or agent, infection can occur primarily intracellularly or extracellularly.

[0087] Bacteria include gram-negative bacteria and gram-positive bacteria. Examples of gram-positive bacteria include, but are not limited to, Pasteurella species, Staphylococcus species, and Streptococcus species. Examples of gram-negative bacteria include, but are not limited to, Escherichia coli, Pseudomonas species, and Salmonella species.Specific examples of infectious bacteria include, but are not limited to, Helicobacter pylori, Borrelia burgdorferi, Legionella pneumophilia, Mycobacteria spp. (e.g., M. tuberculosis, M. avium, M. intracellulare, M. kansasii, M. gordonae), Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyogenes (Group A Streptococcus), Streptococcus agalactiae (Group B Streptococcus), Streptococcus (viridans group), Streptococcus faecalis (Streptococcus pyogenes), Streptococcus spp. faecalis), Streptococcus bovis, Streptococcus (anaerobic spp.), Streptococcus pneumoniae, pathogenic Campylobacter spp., Enterococcus spp., Haemophilus influenzae, Bacillus anthracis, Corynebacterium diphtheriae, Corynebacterium spp., Erysipelothrix rhusiopathiae, Clostridium perfringens, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasturella multocida, Bacteroides spp., Fusobacterium nucleatum, Streptobacillus moniliformis), Treponema pallidum, Treponema pertenue, Leptospira, Rickettsia and Actinomyces israelii.

[0088] Examples of viruses that have been found to cause infection in humans include, but are not limited to: Retroviridae (e.g., human immunodeficiency viruses, such as HIV-1 (also known as HTLV-III), HIV-2, LAV or HTLV-III / LAV or HIV-III and other isolates, such as HIV-LP); Picornaviridae (e.g., poliovirus, hepatitis A virus; enteroviruses, human coxsackieviruses, rhinoviruses, echoviruses); Caliciviridae (e.g., strains that cause gastroenteritis); Togaviridae (e.g., equine encephalitis); The family includes the following: influenza virus; leukemia virus; rubella virus); Flaviviridae (e.g., dengue virus, encephalitis virus, yellow fever virus); Coronaviridae (e.g., coronavirus); Rhabdoviridae (e.g., vesicular stomatitis virus, rabies virus); Filoviridae (e.g., Ebola virus); Paramyxoviridae (e.g., parainfluenza virus, mumps virus, measles virus, respiratory syncytial virus); Orthomyxoviridae (e.g., influenza virus); Bungaviridae (e.g., Hantavirus, Bunyavirus, Phlebotomycin virus, and Nairovirus); viruses); Arenaviridae (hemorrhagic fever viruses); Reoviridae (e.g., reoviruses, orbiviurses, and rotaviruses); Binaviridae; Hepadnaviridae (hepatitis B virus); Parvoviridae (parvoviruses); Papovaviridae (papillomaviruses, polyomaviruses); Adenoviridae (most adenoviruses); Herpesviridae (simple herpesviruses); Herpes simplex virus (HSV) 1 and 2, varicella-zoster virus, cytomegalovirus (CMV), herpes simplex virus; Poxviridae (smallpox, vaccinia, poxvirus); and Iridoviridae (e.g., African swine fever virus); and unclassified viruses (e.g., causative agents of spongiform encephalopathies, hepatitis D agent (thought to be a defective satellite virus of hepatitis B virus), non-A, non-B hepatitis agents (class 1 = enterally transmitted; class 2 = parenterally transmitted (i.e., hepatitis C); Norwalk and related viruses, and astroviruses).

[0089] Examples of fungi include: Aspergillus spp., Blastomyces dermatitidis, Candida albicans, other Candida spp., Coccidioides immitis, Cryptococcus neoformans, Histoplasma capsulatum, Chlamydia trachomatis, Nocardia spp., Pneumocystis carinii.

[0090] Parasites include, but are not limited to, blood-borne and / or tissue parasites such as Anaplasma phagocytophilum, Babesia microti, Babesia divergens, Entamoeba histolytica, Giardia lamblia, Leishmania tropica, Leishmania spp., Leishmania braziliensis, Leishmania donovani, Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax, and Toxoplasma gondii, Trypanosoma gambiae, Plasmodium spp. gambiense) and Trypanosoma rhodesiense (African sleeping sickness), Trypanosoma cruzi (Chagas disease), as well as Toxoplasma gondii, flatworms, and roundworms.

[0091] In certain embodiments, the methods described herein also include administering an antibacterial drug to the subject. An antibacterial drug is an agent that can kill bacteria or inhibit bacterial growth or function. Antibacterial agents that can effectively kill or inhibit a variety of bacteria are generally referred to as broad-spectrum antibiotics. Other types of antibacterial agents are mainly effective against Gram-positive bacteria or Gram-negative bacteria. These types of antibacterial agents are often referred to as narrow-spectrum antibiotics. Other antibacterial agents that are effective against a single organism or disease but ineffective against other types of bacteria are generally referred to as limited-spectrum antibiotics. Antibacterial agents are sometimes classified according to their primary mode of action. In general, antibacterial agents are cell wall synthesis inhibitors, cell membrane inhibitors, protein synthesis inhibitors, nucleic acid synthesis or function inhibitors and / or competitive inhibitors.

[0092] Antimicrobial agents that can be used in the methods described herein include, but are not limited to, natural penicillins, semisynthetic penicillins, clavulanic acid, cephalosporins, bacitracin, ampicillin, carbenicillin, oxacillin, azlocillin, mezlocillin, piperacillin, methicillin, dicloxacillin, nafcillin, cephalothin, cefpirin, cephalexin, cefmandole, cefaclor, cefazolin, 19mmune19al19, cefoxitin, cefotaxime, cefsulodin, cefmetazoxime, cefixime, ceftriaxone, cefoperazone, 19mmune19al19r, latamoxef, carbapenems, imipenem, monobactems, euztreonam, vancomycin, polymyxin, amphotericin B, nystatin, imidazoles, clotrimazole, miconazole, ketoconazole, imipenem, Traconazole, fluconazole, rifampin, ethambutol, tetracycline, chloramphenicol, macrolides, aminoglycosides, streptomycin, kanamycin, tobramycin, amikacin, gentamicin, tetracycline, minocycline, doxycycline, chlortetracycline, erythromycin, roxithromycin, clarithromycin, oleandomycin, azithromycin, chloramphenicol, quinolones, co-trimoxazole, norfloxacin, ciprofloxacin, enoxacin, nalidixic acid, temafloxacin, sulfonamides, gantrisin, and trimethoprim; acetaminophen; sulfaphenylsulfone sodium; alexin; Alexidine; amdinocillin; pivmecillin Pivoxil; Amicycline; Amlofloxacin; Amlofloxacin mesylate; Amikacin; Amikacin sulfate; Para-aminosalicylic acid; Sodium para-aminosalicylate; Amoxicillin; Amphomycin; Ampicillin; Ampicillin sodium; Apacillin sodium; Apramycin; Aspartocin; Astamicin sulfate; Baminomycin; Avoparcin; Azithromycin; Azlocillin; Azlocillin sodium; Bacampicillin hydrochloride; Bacitracin; Bacitracin methylenedisalicylate; Bacitracin zinc; Flavomycin; Calcium benzylbenzene; Erythromycin B; Betamicain sulfate; Biapenem; Binimycin; Biphenamine hydrochloride; Bispyrithione magnesium sulfate Magsulfex); Butikacin; Butikacin sulfate; Capreomycin sulfate; Carbadox; Carbenicillin disodium; Carbenicillin Indanyl Sodium; Carbenicillin Phenyl Sodium; Carbenicillin potassium; Carumonan sodium; Cefaclor; Cefdroxil; Cefmandole; Cefmandole sodium; Cefmandole sodium; Cefaparole; Ceftriaxone; Cefazolin sodium; Cefazolin sodium; Cefbuperazone; Cefdinir; Cefepime;Cefepime hydrochloride; Cefotecol; Cefixime; Cefmenoxime hydrochloride; Cefmetazole; Cefmetazole sodium; Cefonicid Monosodium; Cefonicid Sodium; Cefoperazone Sodium; Cefuroxime; Ceftriaxone Sodium; Cefotetan; Cefotetan Disodium; Ceftiam Hydrochloride; Cefoxitin; Cefxitin Sodium; Cefimidazole; Cefimidazole Sodium; Cefpiramide; Cefpiramide Sodium; Cefpiramide Sulfate; Cefpodoxime Proxetil; Cefprozil; Cefoxime; Cefuroxime Sodium; Cefuroxime Axetil; Cefuroxime Pivoxetil; Cefuroxime Sodium; Cefuroxime Sodium; Cefalexin; Cefalexin Hydrochloride; Cephaloglycin; Cefuroxime; Cefuroxime Sodium; Cefpirin Sodium; Cefradine; Sitocycline Hydrochloride; Chloramphenicol Acetyl; Chloramphenicol; Chloramphenicol Palmito; Chloramphenicol Pantothenate Complex; Chloramphenicol Sodium Succinate; Chlorhexidine Phosphanilate; Chloroxylenol; Chlortetracycline Hydrochloride Bisulfate); Chlortetracycline Hydrochloride; Cinofloxacin; Ciprofloxacin; Ciprofloxacin Hydrochloride; Ciromycin; Clarithromycin; Clinfloxacin Hydrochloride; Clindamycin; Clindamycin Hydrochloride; Clindamycin Palmitate Hydrochloride; Clindamycin Phosphate; Clofazimine; Cloxacillin Benzathine; Cloxacillin Sodium; 5-Chloro-8-Hydroxyquinoline (Cloxyquin); Colistimethate Sodium Methanesulfonate (Colistimethate Sodium; Colistin Sulfate; Coumarin; Coumarin Sodium; Cyclohexillin; Cycloserine; Dalfopristin; Dapsone; Daptomycin; Demeclocycline; Demeclocycline Hydrochloride; Demeclocycline; Denofungin; Trimethoprim; Dicloxacillin; Dicloxacillin Sodium; Dihydrostreptomycin Sulfate; Dithiothiophene; Dierythromycin; Doxycycline; Doxycycline Calcium; Doxycycline Fosfatex; Doxycycline Hydrochloride; Trixoxacin Sodium; Enoxacin; Epicillin; Epitetracyline Hydrochloride; Erythromycin; Erythromycin Acistrate; Erythromycin Estolate; Erythromycin Ethylsuccinate Ethylsuccinate); erythromycin glucoheptonate; erythromycin lactobionate; erythromycin propionate; erythromycin stearate; ethambutol hydrochloride; ethionamide; fleroxacin; flucloxacillin; fludeuterated alanine; flumequine; fosfomycin; fosfomycin tromethamine;Furazolium chloride; Furazolium tartrate tartrate); fusidic acid sodium; fusidic acid; gentamicin sulfate; glomonam; gramicidin; haloprogin; hetacillin; hetacillin potassium; hexedine; ibafoxacin; imipenem; isoconazole; isopamicin; isoniazid; josamycin; kanamycin sulfate; kitasamycin; levofuradon; levopicillin potassium; erythromycin; lincomycin; lincomycin hydrochloride; lomefloxacin; lomefloxacin hydrochloride; lomefloxacin mesylate; loracarb; mafenide; meclocycline; meclocycline sulfosalicylate; meclocycline potassium phosphate; mequindox; meropenem; meclocycline; meclocycline hydrochloride; methicillin; methicillin hippurate; methicillin mandelate; meclocillin sodium; metiprine; metronidazole hydrochloride; phosphorus metronidazole acid; mezlocillin; mezlocillin sodium; minocycline; minocycline hydrochloride; milinomycin hydrochloride; monensin; monensin sodium; nafcillin sodium; nalidixic acid sodium; nalidixic acid; natamycin; neomycin; neomycin palmitate; neomycin sulfate; neomycin undecenoate; netilmicin sulfate; neutramycin; nifuradine; nifuridone; nifuratel; nifuron; nifurdazid; nifuramide; nifupirol; nifuquinazole; nifurthiazole; nitrocycline; nitrofurantoin; nitroamide; norfloxacin; neomycin sodium; ofloxacin; ormeprim; oxacillin sodium; oximemonam; oximemonam sodium; oximemonam; oximemonam sodium; oxolinic acid; oxytetracycline; oxytetracycline calcium; oxytetracycline hydrochloride; padromycin; parachlorophenol; paolomycin; pefloxacin; pefloxacin mesylate Floxacin; Penacillin; Penicillin G benzathine; Penicillin G potassium; Penicillin G procaine; Penicillin G sodium; Penicillin V; Penicillin V benzathine; Penicillin V hydrilamide; Penicillin V potassium; Valaziron sodium; Phenylparaben; Piperacillin sodium; Pibenicillin sodium; Piricillin sodium; Pirimicin hydrochloride; Piramicillin hydrochloride; Piramicillin pamoate; Piramicillin propionate; Polymyxin B sulfate; Porfiromycin; Porpicacin; Pyrazinamide; Zinc pyrithione; Quindecamine acetate; Quinupristin; Racemic thiamphenicol; Ramoplanin; Ranibromycin; Ralomycin; Repimicin; Rifabutin; Riformestane; Rifaxil; Rifatamide; Rifampin; Rifapentine; Rifapentine; Rifaximin; Rollil Cyclin; Rolicycline nitrate; Roxamicin; Roxamicin butyrate; Roxamicin propionate; Roxamicin sodium phosphate; Roxamicin stearate; Rosoxacin; Roxarsone; Roxithromycin; Sancycline; Sanfepenem sodium; Samoxillin; Sapicillin; Sescofungin; Sisomicin; Sisomicin sulfate; Sparfloxacin; Spectinomycin hydrochloride; Spiramycin; Sisomicin hydrochloride; Stromycin; Streptomycin sulfate; Streptomycin isonicotinoinate; Sulfadiazine; Sulfadiazine; Sulfadiazine; Sulfacetamide; Sulfacetamide sodium; Sulfoxetine; Sulfadiazine; Sulfadiazine sodium; Sulfadoxine; Sulfadiaz ...Sulfasalazine; Sulfisothiazole; Sulfathiazole; Sulfapyrazole; Sulfisoxazole; Sulfadimethoxine; Sulfadimethoxazole; Sulfadimethoxazole diethanolamine; Sulfolipids; Sulfopenem; Sultamicillin; Sulfamicillin sodium; Thalamicillin hydrochloride; Teicoplanin; Temafloxacin hydrochloride; Temocillin; Tetracycline; Tetracycline hydrochloride; Tetracycline phosphate complex; Tetracycline; Thiamphenicol; Thiphencillin Potassium; Ticarcillin Cresyl Sodium; Ticarcillin Disodium; Ticarcillin Sodium; Ticlatone; Tiodonium Iodide Chloride Chloride); Tobramycin; Tobramycin sulfate; Tosufloxacin; Trimethoprim; Trimethoprim sulfate; Trisulfone; Troleandomycin; Pro-spectromycin sulfate; Gramicidin; Vancomycin; Vancomycin hydrochloride; Virginiamycin and Zorbamycin.

[0093] In some embodiments, the method further involves administering an antiviral drug to the subject. Antiviral drugs are compounds that prevent viruses from infecting cells or preventing viruses from replicating in cells. Antiviral drugs are much less common than antibacterial drugs because the viral replication process is closely related to DNA replication in host cells, and non-specific antiviral drugs are usually toxic to the host. There are several stages in the process of viral infection that can be blocked or inhibited by antiviral agents. These stages include: viral attachment to host cells (immunoglobulins or binding peptides), viral uncoating (such as adamantane), synthesis or translation of viral mRNA (such as interferon), replication of viral RNA or DNA (such as nucleoside analogs), maturation of new viral proteins (such as protease inhibitors), and budding and release of viruses.

[0094] Nucleotide analogs are synthetic compounds that are similar to nucleotides but have incomplete or abnormal deoxyribose or ribose groups. Once nucleotide analogs enter the cell, they are phosphorylated to produce triphosphates, which compete with normal nucleotides for introduction into viral DNA or RNA. Once the triphosphate form of a nucleotide analog is introduced into a growing nucleic acid chain, it will produce an irreversible association with the viral polymerase, resulting in chain termination. Nucleotide analogs include, but are not limited to, acyclovir (for the treatment of herpes simplex virus and varicella zoster virus), ganciclovir (for the treatment of cytomegalovirus), iodine, ribavirin (for the treatment of respiratory syncytial virus infection), dideoxyinosine, dideoxycytidine, and zidovudine (azidothymidine).

[0095] Interferons are cytokines secreted by virus-infected cells and immune cells. The function of interferons is to bind to specific receptors on cells adjacent to the infected cell, causing changes in the cell that protect it from viral infection. IFN-α and IFN-β also induce the expression of class I and class II MHC molecules on the surface of infected cells, thereby increasing antigen presentation for recognition by host immune cells. These interferons exist in recombinant form and have been used to treat chronic hepatitis B and C infections. While effective in antiviral treatment, interferons can sometimes produce serious side effects such as fever, malaise, and weight loss.

[0096] Immunoglobulin therapy is used to prevent viral infections. Immunoglobulin therapy for viral infections differs from that for bacterial infections because immunoglobulin therapy is not antigen-specific but works by binding to extracellular viral particles and preventing them from attaching to and entering cells susceptible to viral infection. This treatment is useful for preventing viral infections for a period of time while the antibodies are present in the host. There are generally two types of immunoglobulin therapy, normal immunoglobulin therapy and hyperimmune globulin therapy. Normal immunoglobulin therapy uses an antibody product that is prepared and pooled from the sera of normal blood donors. This pooled product contains low titer antibodies against a variety of human viruses, such as hepatitis A, parvovirus, and enterovirus (especially in newborns). Hyperimmune globulin therapy uses antibodies prepared from the sera of individuals with high titer antibodies to a specific virus. These antibodies are then used against the specific virus. Examples of hyperimmune globulins include herpes zoster immune globulin (which can be used to prevent chickenpox in immunocompromised children and neonates), human rabies immune globulin (which can be used for post-exposure prophylaxis of persons bitten by rabid animals), hepatitis B immune globulin (which can be used to prevent hepatitis B virus, particularly in subjects exposed to the virus), and RSV immune globulin (which can be used to treat respiratory syncytial virus infection).

[0097] Therefore, antiviral drugs that can be used in combination with the anti-CEACAM1 antibody formulations described herein include, but are not limited to, immunoglobulins, amantadine, interferon, nucleoside analogs, and protease inhibitors. Specific examples of antiviral agents include, but are not limited to, acemannan; acyclovir; acyclovir sodium; adefovir; alovudine; avesutol; amantadine hydrochloride; alanodine; aridone; ativiridine mesylate; avridine; cidofovir; sipantheline; cytarabine hydrochloride; delavirdine mesylate; deciclovir; didanosine; dioxalide; eduridine; enviradene; enviroxime; famciclovir; famotin hydrochloride; fecitabine; fealuridine; fosfovir ester; foscarnet sodium; foscarnet sodium; ganciclovir; ganciclovir sodium; iodoxuridine; ketoxaban; lamivudine; lobcavir; memotil hydrochloride; metisazone; monolavin; nevirapine; namatevir; penciclovir; pirodavir; ribavirin; rimantadine hydrochloride; ritonavir; saquinavir mesylate; somantadine hydrochloride; sorivudine; vistolon; stavudine; tilorone hydrochloride; trifluridine; valacyclovir hydrochloride; adenosine; adenosine phosphate; adenosine sodium phosphate; viroxime; zalcitabine; zidovudine and vinfoxime.

[0098] In some embodiments, the methods described herein further involve administering an antifungal drug to a subject. Antifungal drugs are drugs that kill or inhibit the growth or function of infected fungi. Antifungal drugs are sometimes classified by their mechanism of action. Some antifungal agents act as cell wall inhibitors by inhibiting glucose synthase. These include but are not limited to brazilfin / ECB. Other antifungal agents act by destroying the integrity of the membrane. These include but are not limited to imidazoles, such as clotrimazole, sertaconazole, fluconazole, itraconazole, ketoconazole, miconazole and voriconazole, as well as FK 463, amphotericin B, BAY38-9502, MK 991, pradimicin, UK 292, butenafine and terbinafine. Other antifungal agents act by decomposing chitin (e.g., chitinase) or immunosuppression (501 cream).

[0099] Thus, antifungal drugs useful in the methods described herein include, but are not limited to, imidazoles, 501 cream and acristocin, ambutin, amorolfine, amphotericin B, azaconazole, azaserine, brazilfinin, BAY 38-9502, bifonazole, phensalamide hydrochloride, bispyrithione magnesium (Bispyrithione Magsulfex), butenafine, butoconazole nitrate, calcium undecylenate, candidacidin, carbol fuchsin, chitinase, chlordentoin, ciclopirox, ciclopirox olamine, cilofungin, sucronazole, clotrimazole, cupramex, dinomycin, dithiopyridine, doconazole, econazole, econazole nitrate, enilconazole, etonan nitrate, fenconazole nitrate, filipin, FK 463, fluconazole, flucytosine, mycotoxin, griseofulvin, hamycin, isoconazole, itraconazole, carafentzine, ketoconazole, lomonomycin, lysogenycin, mepartriptyline, miconazole, miconazole nitrate, MK 991, monensin, monensin sodium, naftifine hydrochloride, neomycin undecylenate, nifuratel, nifuroxol, nitramine hydrochloride, nystatin, octanoic acid, oxiconazole nitrate, oxiconazole nitrate, oxyfungin hydrochloride, paconazole hydrochloride, patrickin, potassium iodide, prunamicin, prochlorperazine, zinc pyrithione, pyrrolidone, rutamycin, sanguinarine chloride, saperconazole, secofungin, selenium sulfide, sertaconazole, sinefungin, sulconazole nitrate, terbinafine, terconazole, thiram, tikralone, tioconazole, tolcitramate, tolindate, tolnaftate, triacetin, triazine, UK 292, undecylenic acid, chloroquine, voriconazole, zinc undecylenate, and zinoconazole hydrochloride.

[0100] In some embodiments, the methods described herein also involve administering an antiparasitic drug to a subject. An antiparasitic drug is an agent that kills infectious parasites or inhibits the growth or function of infectious parasites. Examples of antiparasitic drugs (also referred to as parasiticides) useful in the methods described herein include, but are not limited to, albendazole, amphotericin B, benznidazole, thiobisdichlorophen, chloroquine hydrochloride, chloroquine phosphate, clindamycin, dehydroemetine, diethylcarbamazine, diloxanide furoate, doxycycline, eflornithine, furazolidone, glucocorticoids, halofantrine, diiodoquinol The drugs used include chloramphenicol, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil, chloranil

[0101] Conditions that may benefit from anti-hCEACAM1 monoclonal antibody therapy include those that require enhanced B and T cell responses to immunogens, including cancers such as melanoma, pancreatic cancer, thyroid cancer, lung cancer, colorectal cancer, squamous cell carcinoma, prostate cancer, breast cancer, bladder cancer, and gastric cancer. Antibody

[0102] Antibodies that specifically bind to CEACAM1 can be used to inhibit CEACAM1 activity, thereby treating diseases or disorders in which CEACAM1 is involved in the pathology. The term "antibody" is used in the broadest sense and includes monoclonal antibodies (including full-length or intact monoclonal antibodies), polyclonal antibodies, multivalent antibodies, multispecific antibodies (e.g., bispecific antibodies), antibody fragments and antigen-binding portions thereof (e.g., paratopes, CDRs), as long as they exhibit the desired biological activity and specificity.

[0103] As used herein, "antibody variable domain" refers to the portion of the light chain and heavy chain of an antibody molecule, including the amino acid sequences of the complementary determining regions (CDRs, i.e., CDR1, CDR2, and CDR3) and framework regions (FRs). VH refers to the variable domain of the heavy chain. VL refers to the variable domain of the light chain. The amino acid positions assigned to CDRs and FRs can be defined according to the numbering conventions of Kabat or Chothia. The term "framework region" (FR) refers to those variable domain residues other than the CDR residues. (Kabat et al., Sequences of Proteins of Immunological Interest, 5 th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1987, 1991)) or Chothia (Chothia & Lesk 196 J. Mol. Biol. 901 (1987)).

[0104] The "complementarity determining region" (CDR) of an antibody is the part of the antibody variable domain that (usually) participates in antigen binding. Each variable domain usually has three CDR regions, which are identified as CDR1, CDR2 and CDR3. Each CDR may include amino acid residues from the CDR defined by, for example, Kabat (i.e., about the 24th-34th (L1), 50-56 (L2) and 89-97 (L3) residues in the light chain variable domain, and 31-35 (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain). Each CDR may also include amino acid residues from a "hypervariable loop" (i.e., about the 26th-32nd (L1), 50-52 (L2) and 91-96 (L3) residues in the light chain variable domain, and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chain variable domain (Chothia)). In some cases, CDR may include amino acids from CDR regions and hypervariable loops defined according to Kabat. Kabat residue designations do not always correspond directly to the linear numbering (primary amino acid sequence) of amino acid residues. Compared with strict Kabat numbering, the actual linear amino acid sequence may contain fewer or additional amino acids, which corresponds to the shortening or insertion of the structural components (whether framework or CDR) of the basic variable domain structure. By comparing the sequence of an antibody or its antigen-binding fragment with the "standard" Kabat numbering sequence for homologous residues, the correct Kabat numbering of the residues of a given antibody or its antigen-binding fragment can be determined. For examples of how Kabat numbering is related to the primary amino acid sequence of an antibody, see PCT / US2019 / 065212, which is incorporated by reference as a whole. In addition, CDR can be defined according to the ImMunoGeneTics (IMGT) system (Lefranc, M.-P. et al., Dev. Comp. Immunol., 27, 55-77 (2003)).

[0105] In one embodiment, the antibody or antigen-binding fragment thereof that binds to the GF-CC' surface of the CEACAM1 protein comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region each comprise CDR1, CDR2, and CDR3, and the sequence of CDR1 of the heavy chain variable region (CDR1H) comprises the sequence X 1 HX 2 X 3 S (SEQ ID NO: 1); X 1 is A, D, N or S; X 2 is A or G; and X 3is an amino acid with a hydrophobic side chain, including I or M; the sequence of the heavy chain variable region CDR2 (CDR2H) comprises the sequence TISSGGTYTYYPDSVKG (SEQ ID NO: 2); the sequence of the heavy chain variable region CDR3 (CDR3H) comprises the sequence HX 4 X 5 DYX 6 PX 7 WFAX 8 (SEQ ID NO:3); X 4 is D, G or P; X 5 is F or P; X 6 Is D or F; X 7 is A or Y; and X 8 is L, H or F; the sequence of the light chain variable region CDR1 (CDR1L) comprises the sequence RANSAVSYMY (SEQ ID NO: 4); the sequence of the light chain variable region CDR2 (CDR2L) comprises the sequence LTSNRAT (SEQ ID NO: 5); and the sequence of the light chain variable region CDR3 (CDR3L) comprises the sequence QQX 9 X 10 X 11 X 12 PX 13 T (SEQ ID NO: 6); X 9 W or N; X 10 is S or T; X 11 is A or an amino acid with a neutral hydrophilic side chain, including S, N, and T; X 12 is L, F or N; and X 13 It is P or F.

[0106] In one embodiment, the region comprises SEQ ID NO:2; the sequence of the heavy chain variable region CDR3 comprises SEQ ID NO:8; the sequence of the light chain variable region CDR1 comprises SEQ ID NO:4; the sequence of the light chain variable region CDR2 comprises SEQ ID NO:5; and the sequence of the light chain variable region CDR3 comprises SEQ ID NO:10.

[0107] In one embodiment, the CEACAM1 antibody or its antigen-binding fragment comprises 6 CDRs, wherein: the heavy chain variable region CDR1 sequence comprises SEQ ID NO:7; the heavy chain variable region CDR2 sequence comprises SEQ ID NO:2; the heavy chain variable region CDR3 sequence comprises SEQ ID NO:8; the light chain variable region CDR1 sequence comprises SEQ ID NO:14; the light chain variable region CDR2 sequence comprises SEQ ID NO:5; and the light chain variable region CDR3 sequence comprises SEQ ID NO:9.

[0108] According to certain embodiments, the antibody or antigen-binding fragment thereof is also characterized by a humanized framework to reduce immunogenicity. In certain embodiments, the CDRs of the antibody or antigen-binding fragment thereof are located in a framework obtained from a human antibody or antigen-binding fragment thereof. In other embodiments, the surface exposed framework residues of the intended antibody or antigen-binding fragment thereof are replaced with framework residues of a human antibody or antigen-binding fragment thereof. The CDRs may also be located in a mouse or humanized framework connected to a human constant region (i.e., a chimeric antibody). In a preferred embodiment, the CDRs of the antibody or antigen-binding fragment thereof are located in a framework composited by two or more human antibodies. In such embodiments, the antibody or antigen-binding fragment thereof comprises two or more sequence segments (i.e., "complexes") derived from unrelated human antibody V regions, which are selected to maintain the monoclonal antibody sequences important for antigen binding of the starting precursor anti-human CEACAM1 monoclonal antibody, and the presence of potential T cell epitopes has been filtered out, for example, using "computer tools" (Holgate & Baker, IDrugs. 2009 Apr; 12 (4): 233-7). The close matching of human sequence segments to all parts of the starting antibody V region and the elimination of CD4+ T cell epitopes prior to the synthesis of antibodies or their antigen-binding fragments enable this technology to limit or circumvent immunogenicity while maintaining optimal affinity and specificity by prior analysis of sequences essential for antigen specificity (Holgate & Baker, 2009).

[0109] As used herein, the term "identity" refers to the sequence identity between two nucleic acid molecules or polypeptides. Identity can be determined by comparing the positions in each sequence aligned for comparison purposes. For example, when a position in the compared nucleotide sequences is occupied by the same base, the molecules are identical at that position. The degree of identity between nucleic acid or amino acid sequences is a function of the number of identical or matching nucleotides or amino acids in the shared position. For example, polypeptides having at least 85%, 90%, 95%, 98% or 99% identity to a particular polypeptide described herein and preferably exhibiting substantially the same function, as well as polynucleotides encoding such polypeptides, are contemplated. Methods and computer programs for determining sequence identity and similarity are publicly available and include, but are not limited to, the GCG program package (Devereux et al., Nucleic Acids Research 12:387, 1984), BLASTP, BLASTN, FASTA (Altschul et al., J. Mol. Biol. 215:403 (1990), and the ALIGN program (version 2.0). The well-known Smith Waterman algorithm can also be used to determine similarity. The BLAST program is publicly available from NCBI and other sources (BLAST Manual, Altschul, et al., NCBI NLM NIH, Bethesda, Md. 20894; BLAST 2.0, at ncbi.nlm.nih.gov / blast / ). In comparing sequences, these methods take into account various substitutions, deletions and other modifications.

[0110] In another aspect, the CEACAM1 binding antibody or antigen-binding fragment thereof that binds to the GF-CC' face comprises: (i) a heavy chain variable domain comprising a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the heavy chain variable domain sequence of SEQ ID NO: 11; and / or (ii) a light chain variable domain comprising a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the light chain variable domain sequence of SEQ ID NO:12.

[0111] In some embodiments, amino acid sequence modifications of the antibodies or antigen-binding fragments thereof that bind to CEACAM1 described herein are contemplated. Amino acid sequence variants of antibodies or antigen-binding fragments thereof are prepared by introducing appropriate nucleotide changes into nucleic acids encoding the antibodies or antigen-binding fragments thereof, or by peptide synthesis. Such modifications include, for example, deletions and / or insertions and / or substitutions of residues within the amino acid sequence of the antibodies or antigen-binding fragments thereof. Any combination of deletions, insertions and substitutions is performed to obtain the final construct, as long as the final construct has the desired properties, such as binding specificity, inhibition of biological activity.

[0112] One type of variant is a conservative amino acid substitution variant. These variants have at least one amino acid residue in the antibody or antigen-binding fragment thereof replaced by a different residue with similar side chain properties. Amino acids can be grouped according to the similarity of their side chain properties (see Lehninger, BIOCHEMISTRY (2nd ed., Worth Publishers, New York, 1975): (1) Non-polar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M); (2) Uncharged, polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) Acidic: Asp (D), Glu (E); (4) Basic: Lys (K), Arg (R), His (H). Thus, a non-limiting example of a conservative amino acid substitution is replacing a non-polar amino acid with another non-polar amino acid.

[0113] Alternatively, naturally occurring residues can be divided into the following groups based on common side chain properties: (1) Hydrophobicity: Ala (A), Val (V), Leu (L), Ile (I), Met (M); (2) Neutral hydrophilicity: Ser (S), Thr (T), Cys (C), Asn (N), Gln (Q); (3) Acidic: Asp (D), Glu (E); (4) Basic: Lys (K), Arg (R), His (H); (5) Residues that affect chain orientation: Gly (G), Pro (P); (6) Aromatic: Phe (F), Trp (W), Tyr (Y). Thus, a non-limiting example of a conservative amino acid substitution is replacing a hydrophobic amino acid with another hydrophobic amino acid.

[0114] Further contemplated are amino acid sequence insertions, which may include amino and / or carboxyl terminal fusions ranging in length from one residue to polypeptides containing more than 100 residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include antibodies or antigen-binding fragments thereof with an N-terminal methionyl residue or antibodies or antigen-binding fragments thereof fused to a cytotoxic polypeptide. Other insertional variants of antibodies or antigen-binding fragments thereof include fusing the N-terminus or C-terminus of the antibody or antigen-binding fragment thereof to an enzyme or polypeptide (e.g., biotin) that increases the serum half-life of the antibody or antigen-binding fragment thereof.

[0115] Any cysteine ​​residue that is not involved in maintaining the proper conformation of the antibody or antigen-binding fragment thereof that binds to CEACAM1 may also be substituted with, for example, serine or alanine to improve the oxidative stability of the molecule and prevent aberrant cross-linking.

[0116] Conversely, cysteine ​​bond(s) may be added to the antibody or antigen-binding fragment thereof to improve its stability (particularly where the antibody or antigen-binding fragment thereof is an antibody fragment such as an Fv fragment).

[0117] In some embodiments, the antibody or antigen-binding fragment thereof has an amino acid change that changes the original glycosylation pattern of the antibody or antigen-binding fragment thereof. "Altering the original glycosylation pattern" refers to deleting one or more carbohydrate moieties present in the antibody or antigen-binding fragment thereof, and / or adding one or more glycosylation sites that are not present in the antibody or antigen-binding fragment thereof. Glycosylation of antibodies is usually N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine (where X is any amino acid except proline) are recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Therefore, the presence of any of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose or xylose to a hydroxyamino acid, most commonly serine or threonine, but 5-hydroxyproline or 5-hydroxylysine may also be used. Glycosylation sites are added to the antibody or antigen-binding fragment thereof that binds CEACAMI by changing the amino acid sequence to include one or more of the above tripeptide sequences (for N-linked glycosylation sites). The change can also be achieved by adding or replacing one or more serine or threonine residues to the sequence of the original antibody or antigen-binding fragment thereof (for O-linked glycosylation sites).

[0118] In some embodiments, the CEACAM1 antibody or antigen-binding fragment thereof provided herein is deglycosylated or aglycosylated. In some embodiments, the CEACAM1 antibody or antigen-binding fragment thereof lacks a glycosylation site in the CDR1 of the variable light chain. In some embodiments, the CEACAM1 antibody or antigen-binding fragment thereof lacks a NXS / T consensus sequence in the CDR1 of the variable light chain. In some embodiments, the CEACAM1 antibody or antigen-binding fragment thereof has a mutation in CDR residues 26 and / or 29 (Kabat numbering) of the CDR1 of the variable light chain. When the antibody or antigen-binding fragment thereof comprises an Fc region, the carbohydrate attached thereto may be changed. For example, an antibody having a mature carbohydrate structure attached to the Fc region of the antibody or antigen-binding fragment thereof lacking fucose is described. See, for example, U.S. Patent Publication Nos. 2003 / 0157108; 2004 / 0093621. Antibodies with bisecting N-acetylglucosamine (G1cNAc) in a carbohydrate attached to the Fc region of the antibody or antigen-binding fragment thereof are cited in WO 03 / 011878; U.S. Pat. No. 6,602,684. Antibodies with at least one galactose residue in an oligosaccharide attached to the Fc region of the antibody or antigen-binding fragment thereof are reported in WO 97 / 30087. See also WO 98 / 58964; WO 99 / 22764, relating to antibodies with altered carbohydrates attached to their Fc region.

[0119] In some embodiments, it may be desirable to modify an antibody or antigen-binding fragment thereof that binds to CEACAM1 as described herein with respect to effector function, for example, to enhance antigen-dependent cell-mediated cytotoxicity (ADCC) and / or complement-dependent cytotoxicity (CDC) of the antibody or antigen-binding fragment thereof. This can be achieved by introducing one or more amino acid substitutions into the Fc region of the antibody or antigen-binding fragment thereof. Alternatively or additionally, one or more cysteine ​​residues may be introduced into the Fc region to allow interchain disulfide bond formation in this region. The homodimeric antibody or antigen-binding fragment thereof thus produced may have improved internalization capacity and / or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., 176 J. Exp. Med. 1191 (1992); Shopes, 148 J. Immunol. 2918 (1992). As described by Wolff et al., 53 Cancer Res. 2560 (1993), heterobifunctional cross-linkers can also be used to prepare homodimeric antibodies with enhanced anti-tumor activity. Alternatively, antibodies or antigen-binding fragments thereof having dual Fc regions can be engineered and thus can have enhanced complement lysis and ADCC capabilities. See Stevenson et al., 3 Anti-Cancer Drug Design 219 (1989).

[0120] For example, WO 00 / 42072 describes antibodies with improved ADCC function in the presence of human effector cells, wherein the antibody comprises an amino acid substitution in its Fc region. Preferably, the antibody or antigen-binding fragment thereof with improved ADCC comprises a substitution at position 298, 333 and / or 334 (Eu numbering of residues) of the Fc region. Typically, the altered Fc region is a human IgG1 Fc region comprising or consisting of one, two or three substitutions at these positions. Such substitutions are optionally combined with substitutions that increase C1q binding and / or CDC. Substitutions include Asn297Ala mutations in IgG1 Fc.

[0121] Antibodies with altered C1q binding and / or complement dependent cytotoxicity (CDC) are described in WO 99 / 51642, U.S. Pat. Nos. 6,194,551, 6,242,195, 6,528,624 and 6,538,124. These antibodies comprise an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 313, 333 and / or 334 (Eu numbering of residues) in their Fc region.

[0122] Antibodies with improved binding to neonatal Fc receptor (FcRn) and increased half-life are described in WO00 / 42072 and U.S. Patent Publication No. 2005 / 0014934. These antibodies comprise an Fc region having one or more substitutions therein, wherein the substitutions improve binding of the Fc region to CEACAM1. For example, the Fc region may have a substitution at one or more of positions 238, 250, 256, 265, 272, 286, 303, 305, 307, 311, 312, 314, 317, 340, 356, 360, 362, 376, 378, 380, 382, ​​413, 424, 428 or 434 (Eu numbering of residues). Preferred antibody variants comprising an Fc region with improved CEACAM1 binding comprise amino acid substitutions at one, two or more of positions 307, 380 and 434 (Eu numbering of residues) of its Fc region. In one embodiment, the antibody or antigen-binding fragment thereof has a 307 / 434 mutation. Engineered antibodies that bind to CEACAM1 with three or more (e.g., four) functional antigen-binding sites are also contemplated. See, e.g., U.S. Patent Publication No. US2002 / 0004587. Antibody fragments and types

[0123] In some embodiments of the aspects described herein, the CEACAM1 antibody fragment is a Fab fragment comprising or consisting essentially of the variable (VL) and constant (CL) domains of the light chain and the variable domain (VH) and the first constant domain (CH1) of the heavy chain.

[0124] In some embodiments of the aspects described herein, the CEACAM1 antibody fragment is a Fab' fragment, which refers to a Fab fragment having one or more cysteine ​​residues at the C-terminus of the CH1 domain.

[0125] In some embodiments of the aspects described herein, the CEACAM1 antibody fragment is a Fd fragment comprising or consisting essentially of VH and CH1 domains.

[0126] In some embodiments of the aspects described herein, the CEACAM1 antibody portion is a Fd' fragment comprising the VH and CH1 domains and one or more cysteine ​​residues at the C-terminus of the CH1 domain.

[0127] Single-chain Fv or scFv antibody fragments contain or consist essentially of the VH and VL domains of an antibody, such that these domains are present in a single polypeptide chain. Typically, the Fv polypeptide also contains a polypeptide linker between the VH and VL domains, which allows the scFv to form a desired structure for antigen binding. See, e.g., Pluckthun, 113 Pharmacology Monoclonal Antibodies 269 (Rosenburg & Moore, eds., Springer-Verlag, New York, 1994). Therefore, in some embodiments of the aspects described herein, the CEACAM1 antibody fragment is an Fv fragment that contains or consists essentially of the VL and VH domains of a single arm of an antibody.

[0128] In some embodiments of the aspects described herein, the CEACAM1 antibody portion is a diabody comprising two antigen binding sites comprising a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain.

[0129] In some embodiments of the aspects described herein, the CEACAM1 antibody portion is a dAb fragment comprising or consisting essentially of a VH domain.

[0130] In some embodiments of the aspects described herein, the CEACAM1 antibody portion is a F(ab')2 fragment comprising a bivalent fragment comprising two Fab' fragments linked by a disulfide bridge at the hinge region.

[0131] Linear antibodies are described in Zapata et al., Protein Engin., 8(10):1057-1062 (1995). In short, these antibodies comprise a pair of tandem Fd segments (VH-CH1-VH-CH1) that, together with complementary light chain polypeptides, form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific. In some embodiments of the aspects described herein, the CEACAM1 antibody fragment is a linear antibody comprising a pair of tandem Fd segments (VH-CH1-VH-CH1) that, together with complementary light chain polypeptides, form a pair of antigen binding regions.

[0132] Various techniques have been developed and can be used for the production of antibody fragments. Traditionally, these fragments are obtained by proteolytic digestion of intact antibodies. See, for example, Morimoto et al., 24 J. Biochem. Biophys. Meths. 107 (1992); Brennan et al., 229 Science 81 (1985). However, these fragments can now be produced directly by recombinant host cells. For example, antibody fragments can be isolated from the antibody phage library discussed herein. Alternatively, Fab'-SH fragments can be directly recovered from Escherichia coli and chemically coupled to form F(ab')2 fragments (Carter et al., 1992). According to another method, F(ab')2 fragments can be directly isolated from recombinant host cell cultures. For skilled practitioners, other techniques for producing antibody fragments will be apparent. In other embodiments, the selected antibody fragment is a single-chain Fv fragment (scFv). See, for example, WO 93 / 16185.

[0133] In one embodiment, the antibody is a bispecific antibody comprising a complementary region that binds to CEACAM1 and a complementary region that binds to PD-1.

[0134] In one embodiment, the antibody is a bispecific antibody comprising a complementary region that binds to CEACAM1 and a complementary region that binds to PD-L1.

[0135] The contemplated antibodies or antigen-binding fragments thereof may have constant regions of all types, including IgM, IgG, IgD, and IgE; and any isotype, including IgG1, IgG2, IgG3, and IgG4. In one embodiment, human isotype IgG1 is used. In another embodiment, human isotype IgG4 is used. The light chain constant region may be alpha or kappa. The antibody or antigen-binding fragment thereof may contain sequences from more than one class or isotype. Antibody Binding

[0136] The methods described herein allow for determination of whether a given subject's CEACAM1 (or the subject's cancer's CEACAM1) is inhibited by an antibody that binds to the GF-CC' face of CEACAM1. If an antibody binds effectively to the wild type, but does not bind or binds with reduced affinity to certain allelic variants, it can be predicted based on the CEACAM1 genotype whether a given subject's CEACAM1-mediated disease or disorder is likely to respond (or not respond) to the antibody, or may require higher doses or more frequent administration of the antibody. The human CEACAM1 gene produces 11 isoforms by alternative splicing. Each subtype has a variable (V)-like Ig domain at the amino (N) terminus of the protein. In addition to the CEACAM1-1L and CEACAM1-1S subtypes, the various subtypes also have 2 or 3 constant C2-like Ig domains. Eight CEACAM1 isoforms are anchored to the cell membrane via a transmembrane domain, and three CEACAM1 isoforms (CEACAM1-4C1, -3, and -3C2) lack a transmembrane domain and are secreted. Two isoforms (CEACAM1-3AL and -3AS) have an Alu family repeat sequence (A) between the constant C2-like Ig domain and the transmembrane domain. Transmembrane CEACAM1 isoforms also have a long (L) or short (S) cytoplasmic domain, which is determined by the inclusion or absence of CEACAM1 exon 7 in the message. The CEACAM1 L cytoplasmic domain has two ITIM motifs, which are unique to CEACAM1 among CEACAM family members. In one aspect, the therapeutic anti-CEACAM1 antibody or antigen-binding fragment thereof (including the antibodies described herein by their structural features) binds to the GF-CC' face of the extracellular variable (V)-like Ig domain at the amino (N) terminus of the protein (N domain) of CEACAM1, which domain is common to all subtypes of CEACAM1, including CEACAM1 subtypes 1L, 1S, 3L, 3S, 4L, 4S, 3A1, 3AS, 3, 4C1 and 4C2. In some embodiments, the antibodies and antigen-binding fragments thereof provided bind to human CEACAM1. In some embodiments, the antibodies and antigen-binding fragments thereof provided bind to mammalian CEACAM1. The sequence of the full-length form of CEACAM1 (NCB1 reference sequence NP_p01703.2; UNIPROT ID P13688) is provided as SEQ ID NO: 15 (signal sequence: residues 1-34 of SEQ ID NO: 15; Ig-V N domain: residues 35-142 of SEQ ID NO: 15. The mature form of CEACAM1 (without the signal sequence) is provided as SEQ ID NO: 13.

[0137] As used herein, "binding" of an antibody or antigen-binding fragment thereof to CEACAM1, an epitope on CEACAM1, or in certain embodiments described below, a specific residue on CEACAM1 includes selective interaction of the antibody or antigen-binding fragment thereof with CEACAM1. Thus, binding includes, for example, primary and secondary interactions, including hydrogen bonds, ionic interactions and salt bridges, as well as hydrophilic and hydrophobic interactions.

[0138] In certain embodiments, the CEACAM1 antibodies or antigen-binding fragments thereof described herein are expressed as K D For 10 -5 Up to 10 - 12 mol / L、10 -6 Up to 10 -12 mol / L、10 -7 Up to 10 -12 mol / L、10 -8 Up to 10 -12 mol / L、10 -9 Up to 10 -12 mol / L、10 -10 Up to 10 -12 mol / L, or 10 -11 Up to 10 -12 In other embodiments, the CEACAM1 antibodies or antigen-binding fragments thereof described herein are expressed as K D For 10 -5 Up to 10 -11 mol / L、10 -6 Up to 10 -11 mol / L、10 -7 Up to 10 -11 mol / L、10 -8 Up to 10 - 11 mol / L、10 -9 Up to 10 -11 mol / L, or 10 -10 Up to 10 -11 In other embodiments, the CEACAM1 antibodies or antigen-binding fragments thereof described herein are expressed as K D For 10 -5 Up to 10 -10 mol / L、10 -6 Up to 10 -10 mol / L、10 -7 Up to 10 - 10 mol / L、10 -8 Up to 10 -10mol / L, or 10 -9 Up to 10 -10 In other embodiments, the CEACAM1 antibodies or antigen-binding fragments thereof described herein are expressed as K D For 10 -5 Up to 10 -8 mol / L、10 -6 Up to 10 -8 mol / L, or 10 -7 Up to 10 - 8 mol / L binds to CEACAM1.

[0139] The "specificity" of an antibody refers to the ability of an antibody or antigen-binding fragment thereof (e.g., an anti-CEACAM1 antibody or antigen-binding fragment thereof) to recognize a given epitope within CEACAM1, with little or no detectable reactivity with non-CEACAM1 proteins or other portions of CEACAM1. Specificity can be relatively determined by competition assays or by epitope identification / characterization techniques described herein or equivalent techniques known in the art.

[0140] Epitopes can be formed by continuous amino acids or by non-continuous amino acids juxtaposed by the tertiary folding of proteins. Epitopes formed by continuous amino acids are usually retained when exposed to denaturing solvents, while epitopes formed by tertiary folding are usually lost when treated with denaturing solvents. Epitopes usually include at least 3, more commonly at least 5, about 9, or about 8-10 amino acids in a specific spatial conformation. "Epitopes" include structural units that are conventionally bound by immunoglobulin VH / VL pairs. Epitopes define the minimum binding site of an antibody or its antigen-binding fragment, thereby representing the specific target of an antibody or its antigen-binding fragment. In the case of single-domain antibodies, epitopes represent structural units bound by independent variable domains.

[0141] In one specific embodiment, the contemplated antibody or antigen binding fragment specifically binds to the same epitope as antibody CP08H03 / Vk8 S29A. In another embodiment, the contemplated antibody or antigen binding fragment binds to the same epitope as CP08H03 / CP08F05. For further description of the creation of the CP08 antibody and epitope binding of the CP08 / Vk8 S29A and CP08H03 / CP08F05 antibodies, see International Application No. PCT / US2019 / 065212, which is incorporated herein by reference in its entirety.

[0142] In one aspect, antibodies and antigen-binding fragments thereof (including antibodies described herein by their structural features) specifically bind to at least a portion of the homoaffinity binding domain on CEACAM1 (i.e., the portion of the CEACAM1 protein that participates in the formation of CEACAM1:CEACAM1 homodimers), thereby blocking CEACAM1 homoaffinity interactions. In certain embodiments, provided antibodies or antigen-binding fragments thereof specifically bind to one or more CEACAM1 residues (i.e., Y34, Q44, Q89, N97 of SEQ ID NO: 13) contained in the CC' and FG loops of CEACAM1 and including the YQQN pocket at the CEACAM1:CEACAM1 dimer interface, see Huang et al., Nature. 2015 Jan 15; 517(7534): 386-90.

[0143] As used herein, a "blocking" antibody or "antagonist" antibody is an antibody that inhibits or reduces the biological activity of the antigen to which it binds. For example, in some embodiments, a CEACAM1 antagonist antibody or an antigen-binding fragment thereof binds to CEACAM1 and inhibits the activity of CEACAM1 and / or the binding of CEACAM1 to a heterologous binding partner (such as other CEACAM proteins or TIM-3). Activity inhibition and binding inhibition include partial inhibition. Methods for identifying CEACAM1 antibodies that block CEACAM1 homoaffinity and heteroaffinity interactions are described herein and are known to those skilled in the art. For example, competitive antibodies, cross-blocking antibodies, and cross-blocking antibodies can be identified using any suitable method known in the art, including competitive ELISA or Assays in which binding of a competing antibody or a cross-blocking antibody to human CEACAM1 prevents binding of an antibody disclosed herein, and vice versa.

[0144] In certain embodiments, not all CDRs are directly involved in binding to the antigen. In one embodiment, four of the six CDRs of the CEACAM1 antibody or its antigen-binding fragment are in contact with the antigen. In one embodiment, five of the six CDRs of the CEACAM1 antibody or its antigen-binding fragment are in contact with the antigen. In one embodiment, six of the six CDRs of the CEACAM1 antibody or its antigen-binding fragment are in contact with the antigen. In one embodiment, CDR2H, CDR3H, CDR1L, CDR2L and CDR3L of the CEACAM1 antibody or its antigen-binding fragment are directly involved in binding to the antigen.

[0145] Despite the similarity of the N domains between members of the CEACAM family, in some embodiments, the antibodies or antigen-binding fragments thereof provided herein (including antibodies described herein by their structural features) are selective for CEACAM1. By selectively targeting CEACAM1, embodiments of the present invention can avoid undesirable interference, such as the broad activation function of CEACAM3.

[0146] The terms "selective" and "selectivity" as used herein refer to the preferential binding of an antibody or antigen-binding fragment thereof (i.e., a CEACAM1 antibody or antigen-binding fragment thereof) to a particular region, target or peptide (usually a region or epitope in CEACAM1 rather than one or more other biomolecules, including other CEACAM family members).

[0147] In some embodiments, the CEACAM1 antibody or antigen-binding fragment thereof does not exhibit significant binding to CEACAM3, CEACAM5, CEACAM6 and / or CEACAM8. In some embodiments, the CEACAM1 antibody or antigen-binding fragment thereof does not exhibit detectable binding to CEACAM3, CEACAM5, CEACAM6 and / or CEACAM8. In some embodiments, the affinity of the expected CEACAM1 antibody or antigen-binding fragment thereof to bind to CEACAM1 is at least 10 times stronger than the affinity of the expected CEACAM1 antibody or antigen-binding fragment thereof to bind to another target or polypeptide, such as at least 100 times, at least 1000 times, up to 10,000 times or more.

[0148] In some cases, a CEACAM1 antibody or antigen binding fragment will not bind to CEACAM1. Lack of binding to CEACAM1 occurs when both alleles of the CEACAM1 gene are mutated or varied at A49, Q89, Q44 and / or Y34. These variations may be point mutations that change the amino acid to A49V, Q89H, Q44L and / or Y34C. One or all of the point mutations may occur on one or both alleles of the CEACAM1 gene.

[0149] If an individual is heterozygous for one or more of these variant alleles, antibodies that bind to the wild-type allele may have reduced efficacy in treating a disease or disorder associated with CEACAM1 because the antibody may exhibit reduced affinity or ineffective binding to the variant protein.

[0150] As used herein, "affinity" is determined by the dissociation (K) of an antigen from an antigen-binding protein. D ) equilibrium constant, which is a measure of the binding strength between the antigenic determinant and the antigen binding site on the antigen binding protein (such as an antibody or its antibody fragment).D The smaller the value, the stronger the binding strength between the antigenic determinant and the antigen-binding molecule. Alternatively, affinity can also be expressed as the affinity constant K A , that is, 1 / K D As is clear to the skilled person, affinity can be determined in a manner known per se depending on the specific antigen of interest.

[0151] In one aspect, anti-CEACAM1 antibodies and antigen-binding fragments thereof (including antibodies described herein by their structural features) specifically bind to at least a portion of the binding site on CEACAM1 for one or more other members of the CEACAM family, thereby blocking the interaction of CEACAM1 with one or more other members of the CEACAM family. These CEACAM family members include, but are not limited to, CEACAM3, CEACAM5, CEACAM6, and CEACAM8 (Ramani et al., Anal. Biochem. Jan. 15, 2012; 420(2); 127-38; Scheffrahn et al., J. Immunol. May. 15, 2002; 168(10); 5139-46).

[0152] In one aspect, anti-CEACAM1 antibodies and antigen-binding fragments thereof (including antibodies described herein by their structural features) specifically bind to at least a portion of the binding site for TIM family members on CEACAM1, thereby blocking the interaction of CEACAM1 with TIM family members. In some embodiments, this TIM family member is TIM-3. In some embodiments, CEACAM1 antibodies or antigen-binding fragments thereof specifically bind to one or more of CEACAM1 residues Y34, G41, N42, Q44, Q89, S93, D94, V96 and / or N97 of SEQ ID NO: 13, which residues have been shown to be involved in the binding of CEACAM1 to TIM-3 (Huang et al., Nature. 2015 Jan 15; 517(7534): 386-90).

[0153] To the extent that binding of an anti-CEACAM1 antibody to the GF-CC' face of CEACAM1 can interfere with or disrupt the interaction of the CEACAM1 polypeptide with factors that affect or mediate a CEACAM1-associated disease or disorder, the antibody may provide therapeutic benefit. For completeness, the interaction of CEACAM1 with other factors associated with various pathologies is described herein.

[0154] In one aspect, anti-CEACAM1 antibodies and antigen-binding fragments thereof (including antibodies described herein by their structural features) specifically bind to at least a portion of the binding site for bacterial adhesion surface proteins (adhesins) on CEACAM1, thereby blocking the interaction between CEACAM1 and the adhesin. In certain embodiments, the adhesin is expressed on the surface of CEACAM1-binding pathogens, including but not limited to Escherichia coli (particularly diffusely adherent Escherichia coli (DAEC)), Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria commensalis, Moraxella catarrhalis, Haemophilus influenzae, Haemophilus aegypti, Helicobacter pylori, and / or Salmonella sp.

[0155] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof disrupts the interaction between CEACAM1 and HopQ expressed on the surface of Helicobacter pylori. In one embodiment, the CEACAM1 antibody or antigen-binding fragment specifically binds to one or more of CEACAM1 residues F29, Y34, N42, Q89 and N97, which have been predicted to be involved in the binding of CEACAM1 to HopQ.

[0156] In another embodiment, the CEACAM1 antibody or antigen-binding fragment thereof disrupts the interaction between CEACAM1 and opaque-associated (Opa) adhesion proteins expressed on the surface of Neisseria sp, including, but not limited to, Opa52, Opa65, Opa70, Opa72, Opa73, Opa74, and Opa75. In one embodiment, the CEACAM1 antibody or antigen-binding fragment specifically binds to one or more of CEACAM1 residues Q44 and A49, which have been predicted to be involved in the binding of CEACAM1 to Neisseria Opa proteins.

[0157] In another embodiment, the CEACAM1 antibody or antigen-binding fragment thereof disrupts the interaction between CEACAM1 and the Opa-like protein O1pA expressed on the surface of Moraxella sp.

[0158] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof disrupts the interaction between CEACAM1 and Haemophilus influenzae OMP P1. In one embodiment, the CEACAM1 antibody or antigen-binding fragment specifically binds to one or more of CEACAM1 residues Q44 and A49, which have been predicted to be involved in the binding of CEACAM1 to Haemophilus influenzae OMP P1.

[0159] In another embodiment, the CEACAM1 antibody or antigen binding fragment thereof disrupts the interaction between CEACAM1 and Haemophilus aegypti OMP P1. In one embodiment, the CEACAM1 antibody or antigen binding fragment specifically binds to CEACAM1 residue F29, which has been predicted to be involved in the binding of CEACAM1 to Haemophilus aegypti OMP P1.

[0160] In another embodiment, the CEACAM1 antibody or antigen-binding fragment thereof disrupts the interaction between CEACAM1 and Candida albicans.

[0161] In another embodiment, the CEACAM1 antibody or antigen-binding fragment thereof disrupts the interaction between CEACAM1 and influenza virus (including but not limited to H5N1).

[0162] In another embodiment, the CEACAM1 antibody or antigen-binding fragment thereof described herein inhibits the binding of CEACAM1 to a filarial worm. In one embodiment, the filarial worm is Wuchereria bancrofti. Nucleic Acids

[0163] In some embodiments, nucleic acids encoding CEACAM1 antibodies and antigen-binding fragments thereof, as well as vectors, host cells and expression systems comprising these nucleic acids, can be used to prepare or deliver anti-CEACAM1 antibodies.

[0164] The nucleic acid encoding the CEACAM1 antibody and antigen-binding fragment thereof can be, for example, DNA, cDNA, RNA, synthetically produced DNA or RNA, or a recombinantly produced chimeric nucleic acid molecule comprising any of these polynucleotides alone or in combination. For example, the nucleic acid can include an expression vector comprising a polynucleotide sequence encoding the CEACAM1 antibody or antigen-binding fragment thereof described herein, the polynucleotide sequence being operably linked to an expression control sequence suitable for expression in a eukaryotic and / or prokaryotic host cell. Antibody production and expression system

[0165] The antibodies or antigen-binding fragments thereof described herein are generally produced by recombinant expression. The nucleic acid encoding the light chain variable region and the heavy chain variable region optionally connected to the constant region is inserted into an expression vector. The light chain and the heavy chain can be cloned on the same or different expression vectors. The DNA segment encoding the immunoglobulin chain is operably connected to the control sequence in the expression vector to ensure the expression of the immunoglobulin polypeptide. The expression control sequence includes, but is not limited to, a promoter (e.g., a naturally associated or heterologous promoter), a signal sequence, an enhancer element, and a transcription termination sequence. Preferably, the expression control sequence is a eukaryotic promoter system in a vector capable of transforming or transfecting a eukaryotic host cell. Once the vector is introduced into a suitable host cell, the host cell is maintained under conditions suitable for high-level expression of the nucleotide sequence and collecting and purifying cross-reactive antibodies. For example, an expression system for antibodies is described in PCT / US2019 / 065212, which is incorporated herein by reference. Genomic DNA extraction and genotyping assay

[0166] The methods described herein include genotyping an individual for their CEACAM1 genotype. Such genotyping is typically performed on a biological sample comprising genomic DNA from a subject. There are many suitable methods in the art, including but not limited to DNA sequencing, allele-specific hybridization, PCR, allele-specific amplification (ASA) (WO93 / 22456), allele-specific hybridization, single base extension (U.S. Pat. No. 4,656,127), ARMS-PCR, Taqman (U.S. Pat. Nos. 4,683,202; 4,683,195; and 4,965,188), oligonucleotide ligation assays, single-strand conformation analysis ((SSCP) Orita et al., PNAS 86 2766-2770 (1989)), genetic bit analysis (WO 92 / 15712) and RFLP direct sequencing, mass spectrometry (MALDI-TOF) and DNA arrays. In some embodiments, the biological sample comprises cells, or tissues, or peripheral blood, or body fluids. Exemplary biological samples include, but are not limited to, biopsies, tumor samples, biological fluid samples; blood; serum; plasma; urine; semen; mucus; tissue biopsies; organ biopsies; synovial fluid; bile fluid; cerebrospinal fluid; mucosal secretions; effusions; sweat; saliva; and / or tissue samples, etc. The term also includes mixtures of the above samples. The term "test sample" also includes untreated or pretreated (or preprocessed) biological samples. In some embodiments of any aspect, the test sample may include cells from a subject. In some embodiments of any aspect, the test sample may be a body fluid, an oral swab, or a tumor sample.

[0167] The methods described above may require amplification of a DNA sample from a subject, and this can be accomplished by techniques known in the art such as PCR (see PCR Technology: Principles and Applications for DNA Amplification (ed. HA Erlich, Freeman Press, NY 1992; PCR Protocols: A Guide to methods and Applications (eds. Innis et al., Academic press, San Diego, Calif. 1990); Mattila et al., Nucleic Acids Res. 19 4967 (1991); Eckert et al., PCR Methods and Applications 117 (1991); and US Pat. No. 4,683,202. Other suitable amplification methods include ligase chain reaction (LCR) (Wu et al., Genomics 4 560 (1989); Landegran et al., Science 241 1077 (1988)), transcription amplification (Kwoh et al., Proc Natl Acad Sci USA 86 1173 (1989)), self-sustaining sequence replication (Guatelli et al., Proc Natl Acad Sci USA 87 1874 (1990)), and nucleic acid-based sequence amplification (NASBA). The latter two methods both involve isothermal reactions based on isothermal transcription, producing single-stranded RNA and double-stranded DNA as amplification products at a ratio of 30 or 100 to 1, respectively.

[0168] Exemplary methods for treating test samples include, but are not limited to, centrifugation, filtration, ultrasound, homogenization, heating, freezing and thawing, and combinations thereof. In some embodiments, the test sample can be a frozen test sample, for example, a frozen tissue. The frozen sample can be thawed before the method or assay described herein is adopted. After thawing, the frozen sample can be centrifuged before the method or assay described herein is performed. In some embodiments, the test sample is a clarified test sample, for example, prepared by centrifugation and collecting the supernatant. In some embodiments, the test sample can be a pre-processed test sample, for example, a supernatant or filtrate produced from a treatment selected from centrifugation, filtration, thawing, purification, and any combination thereof. In some embodiments, the test sample can be treated with chemical and / or biological reagents. During storage or processing, chemical and / or biological reagents can be used to protect and / or maintain the stability of the sample, including biomolecules (e.g., nucleic acids and proteins) therein. An exemplary reagent is a protease inhibitor, which is generally used to protect or maintain the stability of proteins during processing. The skilled technician is well aware of the methods and processes for pre-processing of biological samples necessary for determining the level of the expression product described herein.

[0169] In some embodiments of any of the aspects, the methods and assays described herein may further comprise the step of obtaining or having obtained a test sample from a subject.

[0170] Nucleic acid samples derived from cancer cells and non-cancerous cells of a subject that can be used in the methods described herein to determine the genotype of the subject can be prepared by means well known in the art.

[0171] Although the most likely sample for genotyping a subject is a blood sample, in some cases, collecting a nucleic acid sample from a subject can be accomplished, for example, by surgery or aspiration. During a surgical procedure to remove cancerous tissue, the surgeon will typically remove a non-cancerous tissue and / or cell sample of the same tissue type from the cancer patient for comparison. A nucleic acid sample can be isolated from such tissue from the subject for use in the methods described herein. Protein extraction and antibody binding assay / affinity determination

[0172] Where applicable, the amount of CEACAM1 expressed in or around a subject or a cancer or infected tissue of a subject can be determined by methods known in the art, including, for example, ELISA, Western blot, immunohistochemistry, or other immunoassays. Such immunoassays can be performed with antibodies that bind to the GF-CC' face of CEACAM1, or in other embodiments, with antibodies that bind to another epitope. Mass spectrometry can also be used. Standard ELISA techniques known in the art are described in "Methods in Immunodiagnosis", 2nd Edition, Rose and Bigazzi, eds. John Wiley & Sons, 1980; and Oellerich, M. 1984, J. Clin. Chem. Clin. Biochem. 22: 895-904. These references are incorporated herein by reference in their entirety.

[0173] The level below the reference level can be at least about 10%, at least about 20%, at least about 50%, at least about 60%, at least about 80%, at least about 90% or lower relative to the reference level. In some embodiments, the level below the reference level can be a level that is statistically significantly lower than the reference level.

[0174] The level above the reference level can be at least about 10%, at least about 20%, at least about 50%, at least about 60%, at least about 80%, at least about 90%, at least about 100%, at least about 200%, at least about 300%, at least about 500% or more than the reference level. In some embodiments, the level above the reference level can be a level that is statistically significantly higher than the reference level.

[0175] In some embodiments, when a subject is found to be heterozygous for one or more allelic variants of CEACAM1 including A49V, Q89H, Q44L and / or Y34C, the methods described herein may further include assaying a sample containing CEACAM1 from the subject to determine the extent to which the subject's CEACAM1 is bound by an agent comprising an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1. The dose and / or dosing regimen of such an agent may be adjusted based on the extent to which the agent binds to the subject's CEACAM1. That is, if the antibody agent is found to bind to the subject's CEACAM1 protein, but for example, with reduced affinity, the dose and / or dosing frequency of the antibody agent received by the subject may be increased to improve the efficacy. For example, such an increased dose may be proportional to the extent of reduced affinity determined.

[0176] Methods for measuring antibody binding are known to the skilled artisan. These methods include, for example, ELISA (enzyme-linked immunosorbent assay), Western blot, immunoprecipitation, and immunofluorescence assays. For example, antibody dissociation constants and affinities can be determined, for example, by: surface plasmon resonance-based assays (such as the BIAcore assay described in PCT Application Publication No. WO2005 / 012359); Forte Bio Octet TM Assays, enzyme-linked immunosorbent assays (ELISA); and competition assays (e.g., RIA). When the affinity (as described above and appropriately expressed as, for example, K) of an antibody or antigen-binding fragment thereof described herein binds to a first antigen, D A polypeptide is considered to be "specific for" or "binds specifically to" or "selectively binds to" a first target or antigen as compared to a second target or antigen when the affinity (value) of the amino acid sequence or polypeptide is at least 1000 times, 10,000 times or more better than that of the amino acid sequence or polypeptide to another given polypeptide. In general, molecules that "specifically bind", "selectively bind" or "are specific for" a given target will be expressed as K. D For 10 -6 M (1000 nM) or lower to bind, for example, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M or less. Specific binding can be affected by, for example, the affinity and avidity of the polypeptide agent and the concentration of the polypeptide agent. One of ordinary skill in the art can use any suitable method to determine suitable conditions for the selective binding of the polypeptide agent described herein to the target, such as titration of the polypeptide agent in a suitable binding assay. ELISA can be used to provide antibody affinity, such as by competitive ELISA. Other methods for determining the affinity of a given antibody (e.g., an antibody that binds to the GF-CC' face of CEACAM1, such as an antibody agent based on CP08H03 / Vk8 S29A- or CP08H03 / CP08F05) are known in the art. Non-limiting examples include surface plasmon resonance (e.g., by Biacore TM assay) and biomembrane interferometry (BLI), e.g., by Octet TM Assay (Forte Bio). Such an assay can determine the affinity of the antibody for CEACAM1 in a sample from a subject.

[0177] Generally speaking, if the antibody is found to be K D If the antibody binds to CEACAM1 in a subject at a concentration higher than 1 micromolar, it would not be expected that increasing the dose or frequency of administration would be effective. D Above 10 -7If the affinity is within the range of 100 nM to 1 nM, then increasing the dose or frequency of administration would not be expected to be effective. However, when the affinity is within the range of 100 nM to 1 nM, the dose can be adjusted to increase the dose and / or frequency of administration in proportion to the degree of difference in affinity of the same antibody agent binding to wild-type CEACAM. The CEACAM1 antibodies or antigen-binding fragments thereof described herein are as follows: D Binding to CEACAM1: K D For 10 -6 Up to 10 -12 mol / L、10 -7 Up to 10 -12 mol / L、10 -8 Up to 10 -12 mol / L、10 -9 Up to 10 -12 mol / L、10 -10 Up to 10 -12 mol / L or 10 -11 Up to 10 -12 mol / L. Methods for regulating CEACAM1 activity

[0178] In one aspect, the anti-CEACAM1 antibodies and antigen-binding fragments thereof described herein are used to reduce the interaction between CEACAM1 and another member of the CEACAM family (including but not limited to CEACAM1, CEACAM3, CEACAM5, CEACAM6 and CEACAM8). In some embodiments, the antibody or antigen-binding fragment thereof disrupts the homoaffinity interaction between CEACAM1 monomers.

[0179] On the other hand, the anti-CEACAM1 antibodies and antigen-binding fragments thereof described herein are used to reduce the interaction between CEACAM1 and TIM family members (including TIM-3). In some embodiments, the antibody or antigen-binding fragment thereof disrupts the heterologous affinity interaction between CEACAM1 and TIM-3. By using the antibodies and antigen-binding fragments thereof contemplated by the present invention to disrupt the interaction between CEACAM1 and TIM-3, the CEACAM1 inhibitory function can be reversed while maintaining the TIM-3 activation function.

[0180] Inhibition of CEACAM1 can be used to reduce immunosuppression, such as T cell tolerance. Immunosuppression can be mediated by immunosuppressive receptors expressed on the surface of immune cells and their interactions with their ligands. For example, cytotoxic CD8 T cells can enter a "functional exhaustion" or "anergy" state, whereby they express inhibitory receptors, preventing antigen-specific responses such as proliferation and cytokine production. Therefore, by inhibiting the activity and / or expression of such inhibitory receptors, the suppressed, inhibited or anergic immune response to cancer or tumors can be enhanced or de-inhibited. This enhancement or reversal of immune response suppression can lead to greater T cell activity, reactivity and / or ability or receptivity in terms of activation.

[0181] Methods for measuring T cell activity and thus tolerance or relative reduction or lack of activity are known in the art. Therefore, in some embodiments, one or more parameters or markers of T cell tolerance can be measured to determine whether the anti-CEACAM1 antibody or antigen-binding fragment thereof disclosed herein inhibits CEACAM1 activity. As an example, a reduction in the level of factors associated with tolerance may indicate tolerance inhibition, including but not limited to a reduction in IL-2 levels. Other cytokines and factors associated with or involved in tolerance are known in the art. The reduction of T cell tolerance can also be assessed by examining tumor infiltrating lymphocytes or T lymphocytes in lymph nodes draining from established tumors. Such T cells exhibit exhaustion characteristics by expressing cell surface molecules such as PD1, TIM-3 or LAG-3, and reduced secretion of cytokines such as interferon-γ. Thus, in the presence of a CEACAM1 antibody or antigen-binding fragment thereof, evidence of reduced T cell tolerance includes, for example, (a) an increase in the number of T cells having antigenic specificity for a tumor-associated antigen (e.g., as determined by a major histocompatibility complex class I or class II tetramer comprising a tumor-associated peptide) and (b) an increase in the number of T cells that secrete high levels of interferon-γ and cytolytic effector molecules such as granzyme-B, relative to that observed in the absence of the antibody agent. Treatment

[0182] In one aspect, described herein are methods for determining whether a given subject's disease or disorder is likely to respond to a given CEACAM1 antibody agent. In other aspects, described herein are methods for treating subjects whose disease or disorder is found to be likely to respond to a CEACAM1 antibody agent with such agents. In this method, a therapeutically effective amount of an antibody or antigen-binding portion thereof is administered to a mammal in need. Although the antibodies or antigen-binding portions thereof described herein are particularly useful for administration to humans, they can also be administered to other mammals. A "therapeutically effective amount" is an amount of an antibody agent described herein that, when administered to a mammal, effectively produces the desired therapeutic effect.

[0183] In some aspects, the antibody or its antigen-binding fragment binds to CEACAM1 expressed by exhausted T cells or natural killer (NK) cells, thereby restoring T cell and NK cell activity and leading to an increase in anti-tumor response. In other aspects, the antibody or its antigen-binding fragment binds to CEACAM1 expressed by tumor cells, thereby inhibiting tumor cell metastasis and the formation of tumor stem cell niches. On the other hand, the antibody or its antigen-binding fragment binds to CEACAM1 expressed by macrophages associated with fibrosis in the tumor environment, thereby inhibiting fibrosis. On the other hand, the antibody or its antigen-binding fragment binds to CEACAM1 expressed by other stromal cells such as vascular endothelial cells in the tumor microenvironment, thereby inhibiting angiogenesis.

[0184] Therefore, also provided herein are methods of treating a subject with cancer or a tumor and / or reducing tumor growth, comprising administering an effective amount of a CEACAM1 antibody agent as described herein. In this context, "reducing" includes inhibiting and / or reversing, and may relate to, for example, the symptoms of the disease being treated, the presence or size of metastases or micrometastases, the size of a primary tumor, or the presence or size of a dormant tumor.

[0185] "Subject" refers to mammals, including but not limited to humans or non-human mammals, such as cows, horses, dogs, sheep or cats, etc. Individuals and patients are also subjects herein.

[0186] As used herein, the terms "treat / treated / treating / treatment" refer to therapeutic treatment, the purpose of which is to alleviate (lessen) an undesirable physiological condition, disorder or disease, or to obtain a beneficial or desired clinical result. For the purposes of this disclosure, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; reduction of the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the condition, disorder or disease state; delaying the onset or slowing the progression of the condition, disorder or disease; amelioration of the condition, disorder or disease state; and, alleviation (whether partial or complete), enhancement or improvement, whether detectable or undetectable, of the condition, disorder or disease. Treatment includes inducing a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival compared to the expected survival if not receiving treatment. The terms "prevent / prevention" and the like refer to taking action before the onset of an overt disease or disorder to prevent the development of a disease or disorder or to minimize the extent of a disease or disorder, or to slow its progression.

[0187] The embodiments described herein can be used to treat metastasis, which involves the spread of cancer from its primary site to other places in the body. Cancer cells can break away from the primary tumor, infiltrate the lymph and blood vessels, circulate through the bloodstream, and grow (metastasize) in distant lesions in other normal tissues of the body. Metastasis can be local or distant. Metastasis is a continuous process, depending on the tumor cells breaking away from the primary tumor, spreading through the bloodstream, and stopping at a distant site. At the new site, the cells establish a blood supply and can grow to form a life-threatening mass. Both stimulatory and inhibitory molecular pathways within the tumor cells regulate this behavior, and the interaction between the tumor cells and the host cells at the distant site is also important. In addition to monitoring specific symptoms, metastasis is often detected by using magnetic resonance imaging (MRI) scans, computed tomography (CT) scans, blood and platelet counts, liver function studies, chest X-rays, and bone scans alone or in combination.

[0188] Also contemplated are methods for reducing cancer stemness, comprising administering a CEACAM1 antibody agent as described herein. Cancer stemness may refer to the ability of cells to self-renew and produce additional, phenotypically different cell types. Cancer stem cells (CSCs) are cancer cells that exhibit stem cell-like properties. CSCs typically exhibit at least one feature of cancer and are capable of producing at least one additional, phenotypically different cell type. In addition, cancer stem cells have the ability to replicate asymmetrically and symmetrically. It should be understood that cancer stem cells can be produced by differentiated cancer cells that acquire stemness characteristics and / or stem cells that acquire a phenotype associated with cancer cells. In addition, cancer stem cells can reconstruct non-stromal cell types within a tumor.

[0189] CEACAM1 is expressed by a variety of tumor types, and CEACAM1 may modulate or participate in regulating the growth and metastatic behavior of tumors. In another embodiment, CEACAM1 inhibition will reduce tumor growth and metastasis.

[0190] Expression of CEACAM1 in macrophage subsets is associated with fibrosis during carcinogenesis. In another embodiment, CEACAM1 inhibition will reduce tumor-associated fibrosis.

[0191] Cancers that can be treated by the compositions and methods contemplated by the present invention include tumors that are not vascularized or not substantially vascularized as well as vascularized tumors. Cancers can include non-solid tumors (such as hematological tumors, such as leukemias and lymphomas) or can include solid tumors. Types of cancers treated include, but are not limited to, sarcomas, carcinomas and leukemias, lymphomas and myelomas, blastomas, and brain and spinal cord cancers. Adult tumors / cancers and childhood tumors / cancers are also included. More specific examples of these cancers include, but are not limited to, basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and CNS cancer; breast cancer; peritoneal cancer; cervical cancer; choriocarcinoma; colon and rectal cancer; connective tissue cancer; digestive system cancer; endometrial cancer; esophageal cancer; eye cancer; head and neck cancer; stomach cancer (including gastrointestinal cancer); glioblastoma; liver cancer; hepatocellular carcinoma; intraepithelial neoplasm; renal cancer or kidney cancer; laryngeal cancer; leukemia; liver cancer; lung cancer (such as small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma and lung squamous cell carcinoma); lymphoma, including Hodgkin's lymphoma and non-Hodgkin's lymphoma; melanoma; myeloma; neuroblastoma; oral cancer (such as lip, tongue, mouth, pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; respiratory system cancer; salivary gland cancer; sarcoma; skin cancer; squamous cell carcinoma; stomach cancer; testicular cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulvar cancer; and other cancers and sarcomas; as well as B-cell lymphomas (including low-grade / follicular non-Hodgkin lymphoma (NHL); small lymphocytic (SL) NHL; intermediate-grade / follicular NEIL; intermediate-grade diffuse NHL; high-grade immunoblastic NEIL; high-grade lymphoblastic NEIL; high-grade small nonnuclear lytic cell NHL; bulky NEIL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's macroglobulinemia); chronic lymphocytic leukemia (CLL); acute lymphocytic leukemia (ALL); hairy cell leukemia; chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with nevus hamartomatosis, edema (such as associated with brain tumors), and Meigs syndrome. Patients may have more than one type of cancer.

[0192] The efficacy of cancer treatment methods comprising therapeutic formulations of antibodies and antigen-binding fragments thereof described herein can be measured by various endpoints commonly used to evaluate cancer treatments, including but not limited to tumor regression, reduction in tumor weight or size, time to progression, survival, progression-free survival, total remission rate, duration of remission, and quality of life. In terms of cancer, a therapeutically effective amount of a CEACAM1 antibody agent can reduce the number of cancer cells, reduce tumor size, inhibit (i.e., slow down and preferably prevent to a certain extent) the infiltration of cancer cells into peripheral organs, inhibit (i.e., slow down and preferably prevent to a certain extent) tumor metastasis, inhibit tumor growth to a certain extent, and / or alleviate one or more symptoms associated with the disorder to a certain extent. In the case where a patient suffers from more than one type of cancer, a therapeutically effective amount of a CEACAM1 antibody agent is an amount that effectively treats at least one cancer. To the extent that a CEACAM1 antibody agent prevents growth and / or kills existing cancer cells, it can be a cytostatic and / or cytotoxin. For cancer treatment, in vivo efficacy can be measured, for example, by evaluating survival, progression-free survival (PFS), remission rate (RR), duration of remission, and / or quality of life.

[0193] Immune checkpoint proteins interact with specific ligands to send signals to T cells, shutting down or inhibiting T cell function. Cancer cells, by expressing high levels of checkpoint proteins on their surface, can control the function of T cells that enter the tumor microenvironment, thereby inhibiting anticancer immune responses. The immune checkpoint protein programmed death-1 (PD-1) is a key immune checkpoint receptor that is expressed by activated T cells and B cells and mediates immunosuppression. PD-1 is a member of the CD28 family of receptors, which includes CD28, CTLA-4, ICOS, PD-1, and BTLA. Two cell surface glycoprotein ligands for PD-1, programmed death ligand-1 (PD-L1) and programmed death ligand-2 (PD-L2), have been identified and are expressed on antigen presenting cells and many human cancers and have been shown to downregulate T cell activation and cytokine secretion after binding to PD-1 (Freeman et al., 2000; Latchman et al., 2001). Inhibition of the PD-1 / PD-L1 interaction can promote potent antitumor activity. Examples of PD-1 inhibitors include, but are not limited to, Pembrolizumab (MK-3475), Nivolumab (MDX-1106), Cemiplimab-rwlc (REGN2810), Pidilizumab (CT-011), Spartalizumab (PDR001), Tislelizumab (BGB-A317), PF-06801591, AK105, BCD-100, BI 754091, JS001, LZM009, MEDI0680, MGA012, Sym021, TSR-042. Examples of PD-L1 inhibitors include, but are not limited to, Atezolizumab (MPDL3280A), Durvalumab (MEDI4736), Avelumab (MSB0010718C), BGB-A333, CK-301, CS1001, FAZ053, KN035, MDX-1105, MSB2311, SHR-1316.

[0194] However, there are large groups of cancer patients who receive checkpoint inhibitor therapy who (1) do not respond to this type of therapy (innate or primary resistance) or (2) initially respond but eventually develop disease progression (secondary or acquired resistance). Resistant cancers may also be referred to as refractory cancers. PD-1 / CEACAM1 data from PCT / US2019 / 065212 (incorporated herein by reference in its entirety) showed that tumor-associated cells isolated from patients with acquired resistance to PD-1 / PD-L1 inhibitors upregulated CEACAM1 expression relative to tumor-associated cells isolated from naive patients who were not exposed to PD-1 inhibitors. When CEACAM1 is expressed in the context of acquired resistance, cells carrying CEACAM1 are more likely to be effector memory cells rather than central memory cells, which is consistent with the reduced anticancer response in resistant patients.

[0195] Therefore, one of the methods of using CEACAM1 antibody agents described herein is to use such agents to treat patients who are resistant to checkpoint inhibitors (such as PD-1, PD-L1 and / or CTLA-4 inhibitors). In some embodiments, the CEACAM1 antibody used to treat patients who are resistant to PD-1, PD-L1 and / or CTLA-4 inhibitors is CP08H03 / Vk8S29A or CP08H03 / CP08F05 or an agent comprising its antigen binding domain. In some embodiments, the resistance is innate or primary resistance. In some embodiments, the resistance is secondary or acquired resistance. In some embodiments, the CEACAM1 antibody agent administered reverses T cell exhaustion in patients who are resistant to checkpoint inhibitor therapy. Any cancer that exhibits resistance to PD-1, PDL-1 and / or CTLA-4 inhibitors is suitable for treatment with such methods. In some embodiments, the CEACAM1 antibody agent is administered to patients who have not previously received checkpoint inhibitor therapy.

[0196] In another aspect, the method comprises using a CEACAM1 antibody agent to treat patients who are resistant to therapy with other checkpoint inhibitors, including but not limited to PD-L2, B7-H3, B7-H4, BTLA, HVEM, GALS, LAG3, TIM-3, VISTA, KIR, 2B4 (belonging to the CD2 family of molecules, expressed on all NK, γ6 and memory CD8+(4) T cells), CD160 (also known as BY55), CGEN-15049, CHK1 and CHK2 kinases, A2aR and various B-7 family ligands (including but not limited to B7-1, B7-2, B7-DC, B7-H1, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7).

[0197] In another aspect, the method comprises using a CEACAM1 antibody agent to treat a subject in need of reducing and / or preventing mammalian epithelial colonization by Candida albicans and / or bacteria expressing bacterial adhesins, including but not limited to Escherichia coli (particularly diffusely adherent Escherichia coli (DAEC)), Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria commensalis, Moraxella catarrhalis, Haemophilus influenzae, Haemophilus aegypti, Helicobacter pylori, and / or Salmonella sp. In another aspect, the method comprises using a CEACAM1 antibody agent to reduce influenza virus replication and / or to reduce the release of proinflammatory cytokines or chemokines associated with influenza virus infection. In some embodiments, the influenza virus is H5N1. In another aspect, the method comprises using a CEACAM1 antibody agent to treat a subject in need of reducing and / or preventing infection by filarial nematodes, such as Wuchereria bancrofti. In another aspect, the method comprises using a CEACAM1 antibody agent to treat a subject in need of reducing and / or preventing the development of lymphedema and / or hydrocele associated with filarial (e.g., Wuchereria bancrofti) infection. In one embodiment, the method comprises using a CEACAM1 antibody agent to reduce the invasion of filarial worms into the subject's lymphatic system in a subject in need. In one embodiment, the filarial worm is Wuchereria bancrofti. The subject may be infected with more than one of bacteria expressing bacterial adhesins, Candida albicans, influenza virus, and / or filarial worms.

[0198] In another embodiment, the method comprises using a CEACAM1 antibody agent to reduce invasion of the subject's lymphatic system by cancer cells in a subject in need thereof. Pharmaceutical composition

[0199] If genotyping indicates that the subject's disease or disorder can be treated with an anti-CEACAM1 antibody agent (e.g., an agent that binds to the GF-CC' face of CEACAM1, including but not limited to CP08H03 / Vk8 S29A- or CP08H03 / CP08F05-based antibody agents), the antibody agent can include a therapeutically effective amount of a CEACAM1 antibody or antigen-binding fragment thereof described herein, formulated together with one or more pharmaceutically acceptable excipients.

[0200] The dosage of the active agent can vary according to the reason for use, individual subjects and mode of administration. The dosage can be adjusted according to the subject's weight, the subject's age and health, and the tolerance to the compound or composition. For example, depending on the disease, for antibodies or their antigen-binding fragments, this may require 0.1, 1.0, 3.0, 6.0 or 10.0 mg / Kg. For IgG with a molecular mass of 150,000 g / mol (two binding sites), for 5L blood volume, these dosages correspond to binding sites of approximately 18 nM, 180 nM, 540 nM, 1.08 μM and 1.8 μM.

[0201] Active agents and excipients can be formulated into compositions and dosage forms according to methods known in the art. The pharmaceutical compositions of the present invention can be specially formulated in solid or liquid form, including compositions suitable for parenteral administration, such as by subcutaneous, intratumoral, intramuscular or intravenous injection, for example, as sterile solutions or suspensions.

[0202] Therapeutic compositions comprising antibodies or antigen-binding fragments thereof that bind to CEACAM1 can be formulated with one or more pharmaceutically acceptable excipients, which can be pharmaceutically acceptable materials, compositions or vehicles, such as liquid or solid fillers, diluents, carriers, manufacturing aids (e.g., lubricants, talc, magnesium, calcium or zinc stearate, or stearic acid), fillers, salts, surfactants and / or preservatives, solvents or encapsulating materials involved in carrying or transporting the therapeutic compound administered to a subject. Some examples of materials that can serve as pharmaceutically acceptable excipients include: sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; gelatin; talc; waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as ethylene glycol and propylene glycol; polyols, such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers; water; isotonic saline; pH buffer solutions; and other nontoxic, compatible substances used in pharmaceutical formulations.

[0203] Bulking agents are compounds that add mass to the pharmaceutical formulation and contribute to the physical structure of the formulation in lyophilized form. Suitable bulking agents include, for example, mannitol, glycine, polyethylene glycol, and sorbitol.

[0204] The use of surfactants can reduce the aggregation of reconstructed proteins and / or reduce the formation of particles in the reconstructed formulation. The amount of surfactant added can reduce the aggregation of reconstructed proteins and minimize the formation of particles after reconstruction. Suitable surfactants include polysorbates (e.g., polysorbate 20 or 80); Poloxamers (e.g., Poloxamer 188); Triton; sodium dodecyl sulfate (SDS); sodium lauryl sulfate; sodium octyl glucoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl-, or stearyl-sarcosine; linoleyl-, myristyl-, or hexadecyl-betaine; lauramide Propyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmitamidopropyl- or isostearamidopropyl-betaine (e.g., lauramidopropyl); myristamidopropyl-, palmitamidopropyl- or isostearamidopropyl-dimethylamine; sodium methyl cocoyl taurate or disodium methyl oleoyl taurate; and polyethylene glycol, polypropylene glycol, and copolymers of ethylene glycol and propylene glycol (e.g., Pluronics, PF68, etc.).

[0205] Preservatives can be used in the formulations of the invention. Suitable preservatives used in the formulations include octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride (a mixture of alkylbenzyl-dimethylammonium chlorides in which the alkyl groups are long-chain compounds) and benzethonium chloride. Other types of preservatives include aromatic alcohols such as phenol, butyl alcohol and benzyl alcohol; alkyl parabens such as methylparaben or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol and meta-cresol. Other suitable excipients can be found in standard pharmaceutical textbooks, such as "Remington's Pharmaceutical Sciences", The Science and Practice of Pharmacy, 19th Ed. Mack Publishing Company, Easton, Pa., (1995).

[0206] Compositions comprising antibodies or antigen-binding fragments thereof and pharmaceutically acceptable carriers may comprise various concentrations of CEACAM1 antibodies or antigen-binding portions thereof. For example, the composition may comprise 10 mg / mL to 200 mg / mL, 25 mg / mL to 130 mg / mL, 50 mg / mL to 125 mg / mL, 75 mg / mL to 110 mg / mL, or 80 mg / mL to 100 mg / mL of antibodies or antigen-binding fragments thereof. The composition may also comprise about 10 mg / mL, 20 mg / mL, 30 mg / mL, 40 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL, 90 mg / mL, 100 mg / mL, 110 mg / mL, 120 mg / mL, 130 mg / mL, 140 mg / mL, or 150 mg / mL of antibodies or antigen-binding fragments thereof.

[0207] In some embodiments, the composition comprising the antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier is lyophilized and provided as a composition for reconstitution prior to administration. Application method

[0208] In some embodiments, the methods described herein relate to treating a subject suffering from or diagnosed with a CEACAM1-related disease or disorder with an anti-CEACAM1 antibody agent. Subjects suffering from a CEACAM1-related disease or disorder can be identified using current methods for diagnosing CEACAM1-related diseases or disorders, including but not limited to T cell exhaustion, altered immune cell infiltration patterns in the microenvironment, anergic T cells, low levels of T cells, increased regulatory T cells, and / or increased CEACAM1 expression. Symptoms and / or complications of CEACAM1-related diseases or disorders that characterize these conditions and aid in diagnosis are well known in the art and include but are not limited to fatigue, weight loss, abnormal swelling and / or lumps, any new or unknown cause of pain, cough, hoarseness, abnormal bleeding, changes in bowel or bladder habits, fever, night sweats, headaches, vision or hearing problems, or oral changes such as ulcers, bleeding, pain, or numbness.

[0209] The compositions and methods described herein can be applied to a subject suffering from or diagnosed with a CEACAM1-related disease or disorder. In some embodiments, the methods described herein include administering an effective amount of a composition described herein (e.g., a CEACAM1 antibody) to a subject to alleviate the symptoms of a CEACAM1-related disease or disorder. As used herein, "alleviating the symptoms of a CEACAM1-related disease or disorder" refers to improving any condition or symptom associated with a CEACAM1-related disease or disorder. Such reduction is at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, 99% or more (measured by any standard technique) compared to an equivalent untreated control. Various methods for administering the compositions described herein to a subject are known to those skilled in the art. Such methods may include, but are not limited to, oral, parenteral, intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), pulmonary, skin, topical, injection or intratumoral administration. Administration may be local or systemic.

[0210] As used herein, the term "effective amount" refers to the amount of hCEACAM1 antibody or antigen-binding fragment required to alleviate at least one or more symptoms of a disease or disorder, and relates to a pharmaceutical composition in an amount sufficient to provide the desired effect. Thus, the term "therapeutically effective amount" refers to an amount sufficient to provide a specific anti-CEACAM1 effect for a CEACAM1-related disease or disorder when administered to a typical subject. The effective amount used herein in various contexts will also include an amount sufficient to delay the development of disease symptoms, alter the course of disease symptoms (such as, but not limited to, slowing the progression of disease symptoms), or reverse disease symptoms. Therefore, it is generally not practical to specify an exact "effective amount". However, for any given situation, an appropriate "effective amount" can be determined by a person of ordinary skill in the art using only routine experimentation.

[0211] The effective amount, toxicity and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell culture or experimental animals, for example, for determining LD50 (50% population lethal dose) and ED50 (50% population therapeutically effective dose). The dose can vary depending on the dosage form used and the route of administration utilized. The dose ratio between toxicity and therapeutic efficacy is the therapeutic index, which can be expressed as the ratio LD50 / ED50. Compositions and methods with large therapeutic indices are preferred. The therapeutically effective dose can be initially estimated from cell culture assays. The dose can also be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the CEACAM1 antibody or antigen-binding fragment that achieves half-maximal inhibition of symptoms), as determined in cell culture or in an appropriate animal model. The level in plasma can be measured, for example, by high performance liquid chromatography. The effect of any particular dose can be monitored by appropriate bioassays, such as CEACAM1 binding assays, etc. The dose can be determined by a physician and adjusted, if necessary, to accommodate the observed therapeutic effect.

[0212] The effective amount, toxicity and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell culture or experimental animals, for example, to determine the minimum effective dose and / or the maximum tolerated dose. The dosage can vary depending on the dosage form used and the route of administration utilized. The therapeutically effective dose can be initially estimated from cell culture assays. The dosage can also be formulated in animal models to obtain a dosage range between the minimum effective dose and the maximum tolerated dose. The effect of any particular dose can be monitored by appropriate bioassays such as tumor growth and / or size determination, etc. The dosage can be determined by a physician and adjusted, if necessary, to accommodate the observed therapeutic effect.

[0213] In some embodiments, the technology described herein relates to a pharmaceutical composition comprising a CEACAM1 antibody or antigen binding fragment described herein and an optional pharmaceutically acceptable carrier. In some embodiments, the active ingredient of the pharmaceutical composition comprises a CEACAM1 antibody or antigen binding fragment described herein. In some embodiments, the active ingredient of the pharmaceutical composition consists essentially of a CEACAM1 antibody or antigen binding fragment described herein. In some embodiments, the active ingredient of the pharmaceutical composition consists of a CEACAM1 antibody or antigen binding fragment described herein. Pharmaceutically acceptable carriers and diluents include saline, aqueous buffer solutions, solvents and / or dispersion media. The use of such carriers and diluents is well known in the art. Some non-limiting examples of materials that can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, methylcellulose, ethylcellulose, microcrystalline cellulose, and cellulose acetate; (4) tragacanth powder; (5) malt; (6) gelatin; (7) lubricants, such as magnesium stearate, sodium lauryl sulfate, and talc; (8) excipients, such as cocoa butter and suppository wax; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and cellulose acetate. and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol, mannitol, and polyethylene glycol (PEG); (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) pH buffered solutions; (21) polyesters, polycarbonates, and / or polyanhydrides; (22) bulking agents, such as peptides and amino acids, (23) serum components, such as serum albumin, HDL, and LDL; (22) C 2 -C 12 Alcohols, such as ethanol; and (23) other non-toxic compatible substances used in pharmaceutical formulations. Wetting agents, colorants, release agents, coating agents, sweeteners, flavoring agents, fragrances, preservatives and antioxidants may also be present in the formulation. Terms such as "excipient", "carrier", "pharmaceutically acceptable carrier" and the like are used interchangeably herein. In some embodiments, the carrier inhibits degradation of the active agent (e.g., the CEACAM1 antibody or antigen-binding fragment described herein).

[0214] Therapeutic compositions comprising antibodies or antigen-binding fragments thereof can be administered in any convenient manner, including by injection, infusion, implantation or transplantation. The compositions described herein can be administered to a patient subcutaneously, intradermally, intratumorally, intranodally, intramedullaryly, intramuscularly, intracranially, intravenously or intralymphatically or intraperitoneally.

[0215] In certain embodiments, the antibody or its antigen-binding fragment is administered to a mammal by intravenous infusion, i.e., the antibody or its antigen-binding fragment is introduced into the vein of the mammal over a period of time. In certain embodiments, the period of time is about 5 minutes, about 10 minutes, about 30 minutes, about 1 hour, about 2 hours, about 4 hours, or about 8 hours.

[0216] In certain embodiments, the dosage of the compound or composition is applied to the subject, for example, every day, every other day, every two days, every three days, once a week, twice a week, three times a week, once every two weeks, or once a month. In other embodiments, 2, 3 or 4 dosages of the compound or composition are applied to the subject every day, every two days, every three days, once a week, once every two weeks, or once a month. In some embodiments, the dosage of the compound or composition is applied for 2 days, 3 days, 5 days, 7 days, 14 days, 21 days, or 28 days. In certain embodiments, the dosage of the compound or composition is applied for 1 month, 1.5 months, 2 months, 2.5 months, 3 months, 4 months, 5 months, 6 months, or longer. The duration of treatment depends on the result of treatment or the observed benefit. Combination therapy

[0217] In one aspect, the methods described herein include the administration of a CEACAM1 antibody agent administered together with an additional therapeutic agent. Such additional agents include, but are not limited to, cytotoxic agents, chemotherapeutic agents, growth inhibitors, anti-inflammatory agents, anti-cancer agents, anti-neurodegenerative agents, and anti-infective agents. The agents used for such combined therapies may belong to one or more of the above categories. The administration of the antibody agent and the additional therapeutic agent may be simultaneous or continuous. The administration of the antibody or its antigen-binding fragment and the additional therapeutic agent may be separate or as a mixture. In addition, the therapeutic methods contemplated by the present invention may involve treatment combined with one or more cancer therapies selected from the group consisting of antibody therapy, chemotherapy, cytokine therapy, dendritic cell therapy, gene therapy, hormone therapy, laser therapy, and radiotherapy.

[0218] Exemplary additional therapeutic agents also include radionuclides with high energy ionizing radiation that are capable of causing multiple strand breaks in nuclear DNA and are therefore suitable for inducing cell (e.g., cancer cell) death. Typical high energy radionuclides include: 90 Y. 125 I. 131 I. 123 I. 111 In, 105 Rh, 153 Sm, 67 Cu, 67 Ga, 166 Ho, 177 Lu,186 Re and 188 Re. These isotopes generally produce high-energy alpha or beta particles with short path lengths. Such radionuclides kill cells that are in close proximity to them, such as tumor cells to which the radionuclide has attached or entered. They have little or no effect on nonlocal cells and are essentially nonimmunogenic.

[0219] Exemplary additional therapeutic agents also include cytotoxic agents, such as cytostatics (e.g., alkylating agents, DNA synthesis inhibitors, DNA intercalating or cross-linking agents, or DNA-RNA transcription regulators), enzyme inhibitors, gene regulatory agents, cytotoxic nucleosides, tubulin binding agents, hormones and hormone antagonists, anti-angiogenic agents, etc.

[0220] Exemplary additional therapeutic agents also include alkylating agents, such as the anthracycline family (e.g., doxorubicin, carmine, cyclosporin-A, chloroquine, methotrexate, mithramycin, porfiromycin, streptomycin, anthracenediones, and aziridines). In another embodiment, the chemotherapeutic moiety is a cytostatic agent, such as a DNA synthesis inhibitor. Examples of DNA synthesis inhibitors include, but are not limited to, methotrexate and dichloromethotrexate, 3-amino-1,2,4-benzotriazine 1,4-dioxide, aminopterin, cytosine O-D-arabinoside, 5-fluoro-5'-deoxyuridine, 5-fluorouracil, ganciclovir, hydroxyurea, actinomycin-D, and mitomycin C. Exemplary DNA intercalating agents or crosslinking agents include, but are not limited to, bleomycin, carboplatin, carmustine, chlorambucil, cyclophosphamide, cis-dichlorodiaminoplatinum (II) (cisplatin), melphalan, mitoxantrone, and oxaliplatin.

[0221] Exemplary additional therapeutic agents also include transcriptional regulators, such as actinomycin D, daunorubicin, doxorubicin, homoharringtonine and idarubicin. Other exemplary cell inhibitors compatible with the methods described herein include ansamycin benzoquinones, quinone derivatives (e.g., quinolones, genistein, bactacycline), busulfan, ifosfamide, nitrogen mustard, triimidoquinone, serine, carboquinone, indolequinone EO9, diaziridinylbenzoquinone methyl DZQ, triethylenephosphoramide and nitrosourea compounds (e.g., carmustine, lomustine, semustine).

[0222] Exemplary additional therapeutic agents also include cytotoxic nucleosides, e.g., adenosine arabinoside, cytosine arabinoside, 5-fluorouracil, fludarabine, floxuridine, tegafur, and 6-mercaptopurine; tubulin binding agents, such as taxanes (e.g., paclitaxel, docetaxel, taxanes), nocodazole, rhizoxin, dolastatin (e.g., dolastatin-10, -11, or -15), colchicine, and colchicine analogs (colchicine analogs). hicinoids) (e.g., ZD6126), combretastatins (e.g., combretastatin A-4, AVE-6032) and vinca alkaloids (e.g., vinblastine, vincristine, vindesine and vinorelbine (isovinblastine)); anti-angiogenic compounds such as angiostatin K1-3, DL-α-difluoromethylornithine, endostatin, fumagillin, genistein, minocycline, staurosporine and (±)-thalidomide.

[0223] Exemplary additional therapeutic agents also include hormones and hormone antagonists, such as corticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone or medroxyprogesterone), estrogens (e.g., diethylstilbestrol), antiestrogens (e.g., tamoxifen), androgens (e.g., testosterone), aromatase inhibitors (e.g., aminoglutethimide), 17-(allylamino)-17-demethoxygeldanamycin, 4-amino-1,8-naphthalimide, apigenin, brefeldin A, cimetidine, dichloromethylene diphosphonic acid, leuprorelin, luteinizing hormone-releasing hormone, pifithrin-a, rapamycin, sex hormone binding globulin, and thapsigargin.

[0224] Exemplary additional therapeutic agents also include enzyme inhibitors, such as S (+) -camptothecin, curcumin, (-) -deguelin, 5,6-dichlorobenzimidazole furanoside, etoposide, formestane, forsitracin, hispidin, 2-imino-1-imidazole acetic acid (cyclocreatine), lovastatin, trichostatin A, tyrosine phosphorylation inhibitor AG 34 and tyrosine phosphorylation inhibitor AG 879. Exemplary additional therapeutic agents also include gene modulators, such as 5-aza-2 1 -deoxycytidine, 5-azacytidine, cholecalciferol (vitamin D3), 4-hydroxytamoxifen, melatonin, mifepristone, raloxifene, trans-retinal (vitamin A aldehyde), retinoic acid, retinoic acid, 9-cis retinoic acid, 13-cis retinoic acid, retinol (vitamin A), tamoxifen, and troglitazone.

[0225] Exemplary additional therapeutic agents also include cytotoxic agents, for example, pteridine family drugs, diynenes and podophyllotoxins. Particularly useful members of these classes include, for example, methotrexate, podophyllotoxin or podophyllotoxin derivatives, such as etoposide or etoposide phosphate, isovinabine, vindesine, cyclovinblastine, and the like.

[0226] Additional therapeutic agents compatible with the teachings herein also include auristatins (e.g., auristatin E and monomethyl auristatin E), calicheamicin, gramicidin D, maytansines (e.g., maytansine), neocarcinostatin, topotecan, taxanes, cytochalasin B, ethidium bromide, emetine, teniposide, colchicine, dihydroxyanthraquinone, mitoxantrone, procaine, tetracaine, lidocaine, propranolol, puromycin, and analogs or homologs thereof.

[0227] In one embodiment, a CEACAM antibody agent is co-administered with an agent as a checkpoint inhibitor. Such inhibitors may include small molecule inhibitors, or may include antibodies or antigen binding fragments thereof that bind to and block or inhibit immune checkpoint receptors, or antibodies that bind to and block or inhibit immune checkpoint receptor ligands. Illustrative checkpoint molecules that may be targeted to block or inhibit include, but are not limited to, CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, GAL9, LAG3, TIM-3, VISTA, KIR, 2B4 (belonging to the CD2 family of molecules, expressed on all NK, Y6 and memory CD8+ (4) T cells), CD160 (also known as BY55), CGEN-15049, CHK1 and CHK2 kinases, A2aR and various B-7 family ligands. B7 family ligands include but are not limited to B7-1, B7-2, B7-DC, B7-H1, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7. Checkpoint inhibitors include binding and blocking or inhibiting CTLA-4, PDL1, PDL2, PD1, BTLA, HVEM, TIM-3, GAL9, LAG3, VISTA, KIR, 2B4, CD160 and CGEN-15049. One or more active antibodies or their antigen-binding fragments, other binding proteins, biotherapeutics or small molecules. Illustrative immune checkpoint inhibitors include Tremelimumab (CTLA-4 blocking antibody), anti-OX40 and Yervoy / ipilimumab (anti-CTLA-4 checkpoint inhibitors), and PD-1 and PD-L1 inhibitors described above. Checkpoint protein ligands include, but are not limited to, PD-L1, PD-L2, B7-H3, B7-H4, CD28, and CD86.

[0228] In some embodiments, the CEACAM1 antibody agent is administered with a TIGIT, LAP, Podoplanin, Protein C receptor, ICOS, GITR, CD226, or CD160 inhibitor.

[0229] In some embodiments, the CEACAM1 antibody agent is administered with a CTLA-4, PD-1, PD-L1 or PD-L2 inhibitor. In some embodiments, the CEACAM1 antibody agent is administered with a TIM-3 inhibitor.

[0230] It should be understood that the present invention is not limited to the specific molecules, compositions, methodologies or schemes described, as these may vary. Any methods and materials similar or equivalent to the methods or materials described herein can be used in the practice or testing of embodiments of the present invention. It should also be understood that the disclosure of the present invention in this specification includes all possible combinations of such specific features. For example, when a specific feature is disclosed in the context of a specific aspect or embodiment of the present invention or a specific claim, the feature may also be used in combination with other specific aspects and implementation methods of the present invention and / or in its context to the extent possible, and is generally used in the present invention.

[0231] When this document refers to a method comprising more than two defined steps, the defined steps may be performed in any order or simultaneously (unless the context excludes this possibility), and the method may include one or more other steps performed before any defined step, between two of the defined steps, or after all of the defined steps (unless the context excludes these possibilities). Example Example 1: Companion Diagnostics for Human CEACAM1-Directed Therapeutics

[0232] A therapeutic monoclonal antibody candidate has been developed for human therapy (CP08; see, e.g., PCT / US2019 / 065212CP08H03 / Vk8 S29A- or CP08H03 / CP08F05). The structural basis for the binding of this antibody to its target protein, human carcinoembryonic antigen cell adhesion molecule 1 (hCEACAM1), has also been resolved. These studies have shown that the binding of this antibody (CP08) involves amino acids such as glutamine 89 (Q89) and tyrosine 34 (Y34). These two amino acids are affected by allelic variation. This includes the conversion of glutamine 89 to histidine (H) and the conversion of tyrosine 34 to cysteine ​​(C). In addition, an alanine 49 residue was observed to be close to the CP08 contact site and was affected by allelic variation (conversion of alanine 49 to valine (V)). Compared to other similar hCEACAM members (hCEACAM3, hCEACAM5, hCEACAM6), CEACAM1 is unique in that it contains valine at position 49. The valine at position 49 is predicted to affect CP08 binding. These SNPs (A49V, Q89H, Y34C), as well as glutamine 44 to leucine (Q44L), are all contained in a contiguous block at the center of the hCEACAM1 face, where the CP08 antibody binds. Based on studies of its murine parent (5F4), Q44L may also affect drug binding to hCEACAM1. This suggests that humans expressing natural variants at these positions may bind poorly to the CP08 antibody and therefore respond poorly (or not) to therapy with this therapeutic antibody. This hypothesis was tested by generating an A49V and Q89H double mutant of hCEACAM1.

[0233] X-ray crystallography was performed and it was found that the A49V mutation caused a rotamer shift of the phenylalanine (F)29 residue, predicting the formation of a steric clash. The double mutant (A49V, Q89H) was found to be unable to bind CP08. This could predict that people expressing one or both of these mutations would be less responsive or non-responsive to CP08-based therapeutics, respectively. In addition, these four allelic variants were modeled on the hCEACAM1 surface using the previously published hCEACAM1 structure. All four of these allelic variants were found to be present in a contiguous patch located in the center of the GFCC' face, where the CP08 antibody binds. It was found that mutation of hCEACAM1 to the A48V / Q89H double mutant abolished the binding of CP08 to hCEACAM1. Recent studies have shown that 14% of Caucasians and 43% of Africans express the A49V, Q89H haplotype, which predicts that 7% and 21% of these populations, respectively, may not respond to CP08-based drugs if administered. Furthermore, Q44L and Y34C affect the binding of CP08 to hCEACAM1. In addition, all hCEACAM1-directed therapeutic antibodies that bind to the center of the GFCC' face are expected to be affected by these mutations.

[0234] There is currently no guidance on how to accurately apply anti-hCEACAM1 therapeutic antibodies in a population in clinical applications to predict responsive / non-responsive populations. It has not previously been recognized that human allelic variants that characterize the structure of hCEACAM1 can serve as a means to determine the responsiveness of anti-hCEACAM1 therapies and drugs that target the GFCC' face of human CEACAM1, which represents the primary ligand binding site. It is expected that if an individual human carries certain allelic variants, the binding of anti-hCEACAM1 therapeutic antibodies to their target (hCEACAM1) will be absent (homozygous A49V / Q89H haplotype) or diminished (heterozygous A49V, heterozygous Q89H, or heterozygous or heterozygous Y34C and Q44L carriers). Knowing that a patient does or does not have one of these variants allows the selection of the therapy that is most likely to be effective for a given subject. If the subject is found to be homozygous wild-type, the CEACAM1-related disease or disorder will respond to CP08-based antibody therapy.

[0235] Group 1 patients are those found to be compound homozygous for the A49V and Q89H variants. They are considered hCEACAM1 treatment "non-binders" and therefore unlikely to respond to therapeutic agents; these individuals are considered unsuitable for therapeutic administration of CP08-based therapies and are also likely to be non-responders to any antibody that specifically binds to the GF-CC' face of wild-type hCEACAM1.

[0236] Group 2 patients are those subjects who are heterozygous for A49V and / or Q89H or subjects who are found to be carriers of Y34C or Q44L of either zygosity. In this case, these subjects are considered to be possible candidates for treatment with CP08-based antibody therapy, but may require a higher dose of anti-hCEACAM1 antibody therapy to show a response. In one embodiment, the dose of CP08-based antibody agent for such patients can be adjusted based on an assessment of the affinity of the CP08-based antibody agent binding to the subject's hCEACAM1 (see below).

[0237] Group 3 patients are human subjects with homozygous wild-type hCEACAM1 gene and protein derived therefrom. These latter subjects are considered treatment candidates for whom treatment with CP08-based antibody agents may be effective.

[0238] The second level of characterization can be applied to Groups 1 and 2, where tissue samples (blood and / or tumor) are evaluated for binding to the drug. Group 1 and Group 2 subjects who do not show evidence of binding to the therapeutic agent in examination of these tissue samples (perhaps due to lack of hCEACAM1 protein or allelic variants that cannot bind at a certain ratio, such as low levels of hCEACAM1 expression and specific genotypic variants) will not be considered candidates for treatment. Therefore, such knowledge will provide information for treatment decisions.

[0239] To determine the genotype usage of these allelic variants, a body fluid (e.g., blood, saliva) or tissue sample (e.g., buccal swab and / or tumor tissue) is obtained. DNA is extracted from the body fluid or tissue sample. To determine therapeutic antibody binding, a tissue sample (blood or tumor tissue) is prepared as known in the art.

[0240] To determine the subject's genotype, DNA from the subject is assessed for the presence of the A49V, Q89H, Q44L, and Y34C alleles, and their zygosity (homozygosity or heterozygosity) is determined. Methods for achieving this goal include Taqman assays, amplicon sequencing (all four single nucleotide polymorphisms are present on a single exon encoding a protein of 110 amino acids, thus approximately 300 bp), oligonucleotide binding assays, or other assays. Such methods are well known in the art and need not be described in detail here. Individuals found to be compound homozygous for the A49V and Q89H variants (Group 1) are considered to be hCEACAM1 treatment non-binders and are therefore likely to be unresponsive to treatment; these individuals will be considered unsuitable for therapeutic administration of a CP08-based antibody agent and will therefore not be studied further. Such individuals benefit from not being treated with a drug that is unlikely to provide benefit and therefore undergo early treatment with another anti-cancer drug, whether with a different anti-CEACAM1 drug, one or more chemotherapeutic agents, immunotherapy, radiation, surgery, or some combination thereof.

[0241] Human subjects who are considered to belong to Group 2 or Group 3 based on their genotype can then be evaluated for binding of the drug to their tissue or CEACAM proteins extracted therefrom. In this case, for example, cells from peripheral blood are evaluated in solution or after fixation on a fixed surface (e.g., slide, matrix) for solution-based (flow cytometry, mass cytometry) or surface-based (immunohistochemistry [IHC] or immunofluorescence [IF]) assays to detect drug binding and compare to a positive control that will detect hCEACAM1 protein regardless of genotype. These techniques are also well known in the art and do not need to be described in detail here. There are many antibodies that can be used for genotype-independent binding, including, for example, commercially available antibodies that recognize hCEACAM1 domains other than the IgV domain. Tumor tissue can be either mechanically dissociated for the above-mentioned solution-based assays or fixed in a matrix (e.g., OCT, formalin / paraffin) to allow the binding of the therapeutic antibody and comparison to the control by IHC or IF. Such an assay can be quantified to determine the limit of binding of a therapeutic antibody compared to a control antibody using tissue from a genotypically characterized sample expressing hCEACAM1 as a control, a cell system (e.g., human embryonic kidney 293T cells, Hela cells) transfected with genotypically defined proteins expressing wild-type and allelic variants, or a cell line expressing wild-type hCEACAM1 and or genotypic variants generated by Crispr-Cas9 mediated mutagenesis or other methods. Such transfected or manipulated cell lines can be characterized for binding of therapeutic antibodies (compared to control antibodies) by solution or matrix-based methods to establish the lower limit of detection expected using a specific amount of therapeutic or control antibody.

[0242] In another approach, protein can be extracted from tissue and binding to the therapeutic antibody compared to a control using ELISA, immunoblot, surface plasmon resonance, biomembrane interferometry, or a similar type of immunobinding assay and compared to the signal detected with a fixed concentration of wild-type or mutant protein, in the latter case, including various genotype combinations.

[0243] Subjects in Groups 2 and 3 who lack binding to drug and / or control (due to lack of hCEACAM1 expression or hCEACAM1 expression levels associated with a specific genotype showing lower binding) or whose specific binding level to the drug is below a certain limit are not considered treatment candidates for treatment.

[0244] Thus, a method for determining whether a patient will respond or not respond to administration of an anti-hCEACAM1 therapeutic antibody is disclosed. In this method, individuals considered for treatment with an anti-human CEACAM1 therapeutic agent are examined for expression of wild-type or mutant forms (allelic variants) of hCEACAM1 (A49V, Q89H, Q44L and Y34C alleles). Individuals who are compound homozygous for the A49V and Q89H variants are considered "non-binders" for hCEACAM1 treatment and are unlikely to respond to the therapeutic agent. Individuals who are heterozygous for the A49V and / or Q89H variants or are found to be carriers of Y34C or Q44L of either zygosity are possible binders and may respond to the therapeutic agent if administered at an appropriate dose. Individuals with a wild-type configuration of the hCEACAM1 gene (ie, the gene lacks the A49V, Q89H, Q44L and Y34C variant alleles, such that the hCEACAM1 protein is wild-type) will respond to anti-hCEACAM1 monoclonal antibody treatment.

[0245] Anti-CEACAM1 antibodies and anti-CEACAM1 monoclonal antibodies are described in U.S. Patent 9,556,271, WO2013 / 082366 and WO2020 / 118295, the latter describing CP08. Additional anti-CEACAM1 antibodies that can be used as alternatives are described in US2016 / 0376374 and US2020 / 0277398, for example, for subjects for whom CP08-based antibodies do not work. Although the present invention has been disclosed in specific embodiments, those skilled in the art will appreciate that certain substitutions, changes and / or omissions may be made to the embodiments without departing from the spirit of the present invention. Therefore, the above description is exemplary only and should not limit the scope of the present invention. All references, scientific articles, patent publications and any other documents cited herein are incorporated by reference into the substance of their disclosures.

Claims

1. A method, comprising: i) receiving the results of a hCEACAM1 genotyping assay performed on a sample from a subject in need of therapy for a CEACAM1-related disease or disorder; as well as ii) when the subject's hCEACAM1 genotype is homozygous wild type of A49, Q89, Q44 and Y34 or heterozygous of A49V, Q89H, Q44L and / or Y34C, selecting a therapy with an agent comprising an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1, and When the subject's hCEACAM1 genotype is homozygous for A49V, Q89H, Q44L and / or Y34C hCEACAM1 alleles, therapy with an agent other than an agent comprising an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1 is selected.

2. A method comprising: i) genotyping a sample from a subject in need of therapy for a CEACAM1-related disease or disorder to detect the hCEACAM1 genotype of the subject; as well as ii) when the subject's hCEACAM1 genotype is homozygous wild type with respect to A49, Q89, Q44 and Y34 or heterozygous for A49V, Q89H, Q44L and / or Y34C, selecting a therapy with an agent comprising an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1, and When the subject's hCEACAM1 genotype is homozygous for A49V, Q89H, Q44L and / or Y34C hCEACAM1 alleles, therapy with an agent other than an agent comprising an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1 is selected.

3. The method of claim 1 or 2, wherein the subject suffers from or has been diagnosed with a chronic disease.

4. The method of claim 4, wherein the chronic disease is selected from the group consisting of: cancer; persistent infection; and chronic viral infection.

5. The method of any one of claims 1-5, wherein the subject is a human.

6. The method of any one of claims 1-5, wherein the antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1 comprises a heavy chain variable region and a light chain variable region; in, The heavy chain variable region and the light chain variable region each comprise CDR1, CDR2 and CDR3; and in: The sequence of CDR1H comprises the sequence X1HX2X3S (SEQ ID NO: 1); Where X1 is A, D, N or S; wherein X2 is A or G; and wherein X3 is an amino acid having a hydrophobic side chain, including I or M; The sequence of CDR2H comprises the sequence TISSGGTYTYYPDSVKG (SEQ ID NO: 2); The sequence of CDR3H comprises the sequence HX4X5DYX6PX7WFAX8 (SEQ ID NO: 3); Where X4 is D, G or P; Where X5 is F or P; Where X6 is D or F; wherein X7 is A or Y; and Where X8 is L, H or F; The sequence of CDR1L comprises the sequence RANSAVSYMY (SEQ ID NO: 4); the sequence of CDR2L comprises the sequence LTSNRAT (SEQ ID NO: 5); and the sequence of CDR3L comprises the sequence QQX9X 10 X 11 X 12 PX 13 T (SEQ ID NO: 6); Where X9 is W or N; Where X 10 is S or T; Where X 11 is A or an amino acid with a neutral hydrophilic side chain, including S, N, and T; Where X 12 is L, F or N; and Where X 13 It is P or F.

7. The method of any one of claims 1-5, wherein the sample is selected from the group consisting of a blood sample, a tissue sample, a tumor sample, and a cell sample.

8. The method of any one of claims 1-5, wherein the genotyping assay comprises direct probe testing, allele-specific hybridization, PCR, allele-specific amplification (ASA), single base extension, ARMS-PCR, Taqman, oligonucleotide ligation assay, single strand conformation analysis (SSCP), genetic locus analysis and RFLP direct sequencing, mass spectrometry (MALDI-TOF) and DNA array.

9. The method of any one of claims 1-5, further comprising administering the selected therapy.

10. The method of any one of claims 1 to 9, further comprising, when the CEACAM1 genotype is heterozygous for A49V, Q89H, Q44L and / or Y34C, assaying a sample containing CEACAM1 from the subject to determine the extent to which the subject's CEACAM1 is bound by the agent comprising an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1, and adjusting the amount and / or dosage of the agent to be administered according to the extent to which the agent binds to the subject's CEACAM1.

11. The method of claim 10, wherein the assay comprises a method selected from the group consisting of flow cytometry, mass cytometry, immunohistochemistry, immunofluorescence or FRET assays, surface plasmon resonance, radioimmunoassays, and biomembrane interferometry.

12. The method of claim 2, further comprising, prior to the genotyping, a step of extracting genomic DNA from a sample obtained from the subject.

13. A method of treating a CEACAM1-related disease or disorder in a subject in need thereof, the method comprising: i) genotyping a sample from the subject to detect the hCEACAM1 genotype of the subject; as well as ii) administering a therapeutically effective amount of an agent comprising an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1 when the subject's hCEACAM1 genotype is homozygous wild type of A49, Q89, Q44 and Y34; and iii) when the hCEACAM1 genotype of the subject is heterozygous for A49V, Q89H, Q44L and / or Y34C, assaying a sample containing CEACAM1 from the subject to determine the extent to which the subject's CEACAM1 is bound by the agent comprising an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1, and administering a therapeutically effective amount of the agent, wherein the amount or dosage regimen of the agent to be administered is adjusted according to the extent to which the agent binds to the subject's CEACAM1; and iv) when the subject's hCEACAM1 genotype is homozygous for A49V, Q89H, Q44L and / or Y34C, a therapy comprising administering a therapeutically effective amount of an agent other than an agent comprising an antibody or antigen-binding domain that binds to an epitope in the GF-CC' domain of CEACAM1, Thereby, the CEACAM1-related disease or disorder is treated.

14. The method of claim 13, wherein the subject suffers from or has been diagnosed with a chronic disease.

15. The method of claim 14, wherein the chronic disease is selected from the group consisting of: cancer; persistent infection; and chronic viral infection.

16. The method of any one of claims 13-15, wherein the subject is a human.

17. The method of any one of claims 13-16, wherein the antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1 comprises a heavy chain variable region and a light chain variable region; in, The heavy chain variable region and the light chain variable region each comprise CDR1, CDR2 and CDR3; and in: The sequence of CDR1H comprises the sequence X1HX2X3S (SEQ ID NO: 1); Where X1 is A, D, N or S; wherein X2 is A or G; and wherein X3 is an amino acid having a hydrophobic side chain, including I or M; The sequence of CDR2H comprises the sequence TISSGGTYTYYPDSVKG (SEQ ID NO: 2); The sequence of CDR3H comprises the sequence HX4X5DYX6PX7WFAX8 (SEQ ID NO: 3); Where X4 is D, G or P; Where X5 is F or P; Where X6 is D or F; wherein X7 is A or Y; and Where X8 is L, H or F; The sequence of CDR1L comprises the sequence RANSAVSYMY (SEQ ID NO: 4); the sequence of CDR2L comprises the sequence LTSNRAT (SEQ ID NO: 5); and the sequence of CDR3L comprises the sequence QQX9X 10 X 11 X 12 PX 13 T (SEQ ID NO: 6); Where X9 is W or N; Where X 10 is S or T; Where X 11 is A or an amino acid with a neutral hydrophilic side chain, including S, N, and T; Where X 12 is L, F or N; and Where X 13 It is P or F.

18. The method of any one of claims 13-17, wherein the sample is selected from the group consisting of a blood sample, a tissue sample, a tumor sample, and a cell sample.

19. The method of any one of claims 13-18, wherein the genotyping assay comprises direct probe test, allele specific hybridization, PCR, allele specific amplification (ASA), single base extension, ARMS-PCR, Taqman, oligonucleotide ligation assay, single strand conformation analysis (SSCP), genetic locus analysis and RFLP direct sequencing, mass spectrometry (MALDI-TOF) and DNA array.

20. The method of any one of claims 13-19, wherein assaying a sample containing CEACAM1 from the subject to determine the extent to which the subject's CEACAM1 is bound by the agent comprises a method selected from flow cytometry, mass cytometry, immunohistochemistry, immunofluorescence or FRET assays, surface plasmon resonance, radioimmunoassays, and biomembrane interferometry.

21. An assay comprising: i) extracting genomic DNA from a biological sample from a subject in need of therapy for a CEACAM1-related disease or disorder; ii) genotyping the subject's DNA for sequences corresponding to CEACAM A49, Q89, Q44 and Y34 to determine whether the subject is homozygous wild type for A49, Q89, Q44 and Y34, or is homozygous or heterozygous for each of A49V, Q89H, Q44L and Y34C.

22. The assay of claim 21, wherein the CEACAM1-associated disease or disorder is selected from the group consisting of: cancer; persistent infection; and chronic viral infection.

23. The assay of claim 21 or 22, wherein the subject is a human.

24. The assay of any one of claims 21-23, wherein the biological sample is selected from the group consisting of a blood sample, a tissue sample, a tumor sample, and a cell sample.

25. An assay as described in any of claims 21-24, wherein the genotyping comprises direct probe testing, allele specific hybridization, PCR, allele specific amplification (ASA), single base extension, ARMS-PCR, Taqman, oligonucleotide ligation assay, single strand conformation analysis (SSCP), genetic locus analysis and RFLP direct sequencing, mass spectrometry (MALDI-TOF) and DNA array.

26. The assay of any one of claims 21-25, further comprising iii) assaying the subject's CEACAM1 protein to determine the extent to which the subject's CEACAM1 is bound by an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1.

27. The assay of claim 27, wherein the assay of step (iii) comprises a method selected from flow cytometry, mass cytometry, immunohistochemistry, immunofluorescence or FRET assay, surface plasmon resonance, radioimmunoassay, and biomembrane interferometry.

28. An assay comprising: i) extracting a protein comprising CEACAM1 from a biological sample from a subject in need of a therapy for a CEACAM1-related disease or disorder; ii) assaying the extracted protein for the subject's CEACAM1 to determine the extent to which the subject's CEACAM1 is bound by an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1.

29. The assay of claim 28, wherein the assay of step (ii) comprises a method selected from flow cytometry, mass cytometry, immunohistochemistry, immunofluorescence or FRET assays, surface plasmon resonance, radioimmunoassays, and biomembrane interferometry.

30. The assay of claim 28 or 29, further comprising iii) genotyping the subject's DNA for sequences corresponding to CEACAM A49, Q89, Q44 and Y34 to determine whether the subject is homozygous wild type for A49, Q89, Q44 and Y34, or is homozygous or heterozygous for each of A49V, Q89H, Q44L and Y34C.

31. An assay as described in claim 30, wherein the genotyping includes direct probe testing, allele specific hybridization, PCR, allele specific amplification (ASA), single base extension, ARMS-PCR, Taqman, oligonucleotide ligation assay, single strand conformation analysis (SSCP), genetic locus analysis and RFLP direct sequencing, mass spectrometry (MALDI-TOF) and DNA array.

32. A method for selecting hCEACAM1 antibody therapy for a subject in need thereof, the method comprising: analyzing genomic DNA from a biological sample taken from the subject for the subject's genotype of hCEACAM1 alleles at loci corresponding to A49, Q89, Q44, and Y34, and When the genotype is found to be homozygous for A49, Q89, Q44, and Y34, or heterozygous for one or more of A49V, Q89H, Q44L, and Y34C alleles for CEACAM1, selecting therapy with an agent comprising an hCEACAM1 antibody or antigen-binding fragment thereof that binds to an epitope in the GF-CC' domain of CEACAM1; or When the genotype is found to be homozygous for one or more of the A49V, Q89H, Q44L and Y34C alleles for CEACAM1, therapy with an agent other than the agent comprising an hCEACAM1 antibody or antigen-binding fragment thereof that binds to an epitope in the GF-CC' domain of CEACAM1 is selected.

33. The method of claim 32, wherein the subject suffers from or has been diagnosed with a chronic disease.

34. The method of claim 33, wherein the chronic disease is selected from the group consisting of: cancer; persistent infection; and chronic viral infection.

35. The method of any one of claims 32-34, wherein the subject is a human.

36. The method of any one of claims 32-35, wherein the antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1 comprises a heavy chain variable region and a light chain variable region; in, The heavy chain variable region and the light chain variable region each comprise CDR1, CDR2 and CDR3; and in: The sequence of CDR1H comprises the sequence X1HX2X3S (SEQ ID NO: 1); Where X1 is A, D, N or S; wherein X2 is A or G; and wherein X3 is an amino acid having a hydrophobic side chain, including I or M; The sequence of CDR2H comprises the sequence TISSGGTYTYYPDSVKG (SEQ ID NO: 2); The sequence of CDR3H comprises the sequence HX4X5DYX6PX7WFAX8 (SEQ ID NO: 3); Where X4 is D, G or P; Where X5 is F or P; Where X6 is D or F; wherein X7 is A or Y; and Where X8 is L, H or F; The sequence of CDR1L comprises the sequence RANSAVSYMY (SEQ ID NO: 4); the sequence of CDR2L comprises the sequence LTSNRAT (SEQ ID NO: 5); and the sequence of CDR3L comprises the sequence QQX9X 10 X 11 X 12 PX 13 T (SEQ ID NO: 6); Where X9 is W or N; Where X 10 is S or T; Where X 11 is A or an amino acid with a neutral hydrophilic side chain, including S, N, and T; Where X 12 is L, F or N; and Where X 13 It is P or F.

37. The method of any one of claims 32-36, wherein the sample is selected from the group consisting of a blood sample, a tissue sample, a tumor sample, and a cell sample.

38. The method of any one of claims 32-37, wherein the genotyping analysis comprises direct probe testing, allele-specific hybridization, PCR, allele-specific amplification (ASA), single base extension, ARMS-PCR, Taqman, oligonucleotide ligation assay, single strand conformation analysis (SSCP), genetic bit analysis and RFLP direct sequencing, mass spectrometry (MALDI-TOF) and DNA array.

39. The method of any one of claims 32-38, further comprising administering the selected therapy.

40. The method of any one of claims 32-39, further comprising, when the CEACAM1 genotype is A49V, Q89H, Q44L and / or Y34C heterozygous, assaying a sample containing CEACAM1 from the subject to determine the extent to which the subject's CEACAM1 is bound by the agent comprising an antibody or antigen binding domain that binds to an epitope in the GF-CC' domain of CEACAM1, and adjusting the amount and / or dosage of the agent to be administered based on the extent of binding to the subject's CEACAM1.

41. The method of claim 40, wherein the assay comprises a method selected from flow cytometry, mass cytometry, immunohistochemistry, immunofluorescence or FRET assays, surface plasmon resonance, radioimmunoassays, and biomembrane interferometry.